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Abstract
Macrophage nitric oxide (NO) production and hypoxia coexist during wound healing, and have been
implicated in the pathogenesis and pathophysiology of multiple disease states including sepsis and
cancer. Macrophages stimulated with pathogen associated molecular patterns (PAMPs) produce NO via
inducible nitric oxide synthase (iNOS) from molecular O2, L-arginine, and NADPH. The first aim of this
research was to characterize the degree and duration of hypoxia which would limit NO production by
PAMPs stimulated macrophages. The second aim was to identify the contributing mechanism(s). Using a
novel forced convection cell culture system, we demonstrated that NO production was rapidly (within
seconds) and reversibly regulated by physiological and pathophysiological O2 tensions (pO2). The effect
of pO2 on NO production was not mediated by changes in iNOS protein concentration or iNOS
dimerization, implicating limitation of the reactant(s) as the predominant causative mechanism. In
addition to O2 limitation, hypoxia has the potential to affect NADPH and L-arginine availability. In PAMPs
stimulated macrophages, NADPH is predominantly produced by the oxidative pentose phosphate cycle
(OPPC). NO production directly correlated with OPPC activity over a wide range of pO2, and inhibition of
NO production with the specific iNOS inhibitor, 1400W, significantly decreased OPPC activity. OPPC
activity increased significantly in response to chemically mediated oxidative stress irrespective of pO2,
and NO production was unaffected by increasing cellular oxidative stress, indicating that NADPH
availability for NO production was not limited by hypoxia. L-arginine is required for iNOS dimerization, and
iNOS dimerization was maintained or increased during hypoxic exposure, suggesting sufficient L-arginine
was available. Furthermore, the effect of L-arginine depletion on NO production was much slower than the
response observed due to changes in pO2. In conclusion, decreased O2 availability is the predominant
mechanism responsible for rapidly and reversibly limiting NO production by PAMPs stimulated
macrophages exposed to acute hypoxia.
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ABSTRACT
CHAGES IN OXYGEN TENSION RAPIDLY AND REVERSIBLY REGULATE
MACROPHAGE NITRIC OXIDE PRODUCTION
Mary A. Robinson
Advisors: Cynthia M. Otto and Cameron J. Koch

Macrophage nitric oxide (NO) production and hypoxia coexist during wound
healing, and have been implicated in the pathogenesis and pathophysiology of multiple
disease states including sepsis and cancer. Macrophages stimulated with pathogen
associated molecular patterns (PAMPs) produce NO via inducible nitric oxide synthase
(iNOS) from molecular O2, L-arginine, and NADPH. The first aim of this research was
to characterize the degree and duration of hypoxia which would limit NO production by
PAMPs stimulated macrophages. The second aim was to identify the contributing
mechanism(s). Using a novel forced convection cell culture system, we demonstrated
that NO production was rapidly (within seconds) and reversibly regulated by
physiological and pathophysiological O2 tensions (pO2). The effect of pO2 on NO
production was not mediated by changes in iNOS protein concentration or iNOS
dimerization, implicating limitation of the reactant(s) as the predominant causative
mechanism. In addition to O2 limitation, hypoxia has the potential to affect NADPH and
L-arginine availability. In PAMPs stimulated macrophages, NADPH is predominantly
produced by the oxidative pentose phosphate cycle (OPPC). NO production directly
correlated with OPPC activity over a wide range of pO2, and inhibition of NO production
with the specific iNOS inhibitor, 1400W, significantly decreased OPPC activity. OPPC
activity increased significantly in response to chemically mediated oxidative stress
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irrespective of pO2, and NO production was unaffected by increasing cellular oxidative
stress, indicating that NADPH availability for NO production was not limited by hypoxia.
L-arginine is required for iNOS dimerization, and iNOS dimerization was maintained or
increased during hypoxic exposure, suggesting sufficient L-arginine was available.
Furthermore, the effect of L-arginine depletion on NO production was much slower than
the response observed due to changes in pO2. In conclusion, decreased O2 availability is
the predominant mechanism responsible for rapidly and reversibly limiting NO
production by PAMPs stimulated macrophages exposed to acute hypoxia.
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INTRODUCTION

Macrophage NO Production
Macrophages are found throughout vertebrate and invertebrate tissues at all stages
of life. They mediate tissue development and maintenance, and innate (pathogen pattern
recognition) and adaptive (antigen presentation to T cells) immunity, but are also
implicated in many disease states (208). The mononuclear phagocytic system classifies
adult vertebrate macrophages based on their tissue phenotype and currently includes:
inflammatory macrophages (M1 macrophages, aka classically activated macrophages),
alternatively activated macrophages (M2 macrophages), dendritic cells, and tissueresident macrophages such as alveolar macrophages (lung), osteoclasts and bone marrow
macrophages (bone), microglia (brain), Langerhans cells (dendritic cells in the skin),
crypt macrophages (intestine), Kupffer cells (liver), uterine dendritic cells and uterine
macrophages (208).
Macrophages are bone marrow derived myeloid cells, and are continuously
repopulated (84). Repopulation commonly occurs by extravasation and differentiation of
monocytes from systemic circulation; half of the blood monocytes leave systemic
circulation daily (84). Two populations of monocytes have been identified in circulation,
one which responds to inflammation (M1 and M2 macrophages, dendritic cells), and one
which repopulates noninflamed tissues (resident macrophages, some dendritic cells eg.
Langerhans cells) (84). Thus, the monocyte lineage and the tissue microenvironment
dictate monocyte extravasation, differentiation, and macrophage phenotype.
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Macrophages exposed to bacterial and parasitic components, collectively termed
pathogen associated molecular patterns (PAMPs), and to cytokines such as interferonγ
(IFNγ), were among the first macrophages to be investigated as part of the innate immune
system, and are referred to as classically activated or M1 macrophages (123, 208). A key
component of the M1 macrophage phenotype is the production of nitric oxide (NO) by
inducible nitric oxide synthase (iNOS) from molecular O2, L-arginine, and NADPH (148,
155, 245). The ability of M1 macrophages to produce NO is essential for the effective
elimination of several types of infections (6, 94, 96, 215, 265). However, dendritic cells
(233), microglia cells (14, 210, 234), and some tumor associated macrophages (typically
thought to be M2 macrophages) (102), have also been demonstrated to upregulate iNOS,
suggesting NO production and its effects may not be limited to M1 macrophages. In our
studies of NO production, two stimuli known to induce macrophage iNOS were utilized:
lipopolysaccharide (LPS) and IFNγ.
LPS is the primary component of the outer membrane of gram-negative bacteria
(5). LPS binding to CD14 and TLR4/MD2 on the macrophage cell surface results in
signaling through multiple adaptor proteins including Src kinases, protein kinase C, PI3kinase, mitogen activated protein kinases, phospholipase D, Gi/Go proteins, protein
kinase A, FKBP12-rapamycin-associated protein, MyD88, IRAK, and TRAF6 (5, 25).
Signaling through these proteins activates the transcription factors, NFκB, C/EBP, AP-1
(5, 25), and even HIF1 in normoxic differentiated macrophages (31, 195). NFκB, NFIL6 (a C/EBP transcription factor), and HIF1 have been shown to bind to regions in the
iNOS promoter and upregulate iNOS transcription (63, 95, 126, 163, 170, 181, 205, 288).
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IFNγ is produced by activated T lymphocytes and natural killer cells, and acts in a
paracrine manner on macrophages (19, 60). IFNγ binds to the IFNγ receptor, which
signals through the adaptor proteins JAK2, MEK1/2, and Erk1/Erk2 to activate the
transcription factor STAT1α (19, 29). STAT1α binds to the iNOS promoter (80, 170,
288), and to the IRF-1 promoter (146), at the gamma-interferon activated site. STAT1α
and IRF-1 binding to the iNOS promoter is necessary for IFNγ mediated upregulation of
iNOS transcription (80, 139, 170, 174).
LPS and IFNγ treatment of macrophages results in the upregulation of iNOS
mRNA by 3 hours, and protein by 6 hours, with maximal protein concentration and
activity observed at 24 hours (4, 61). NO production continues for up to 2 days (9), at
which point the cells die via apoptosis (8, 224), most likely mediated by the continued
exposure to nitrosative stress (103, 173). iNOS cleavage and degradation by calpain 1
(267, 268) and the ubiquitin-proteosome pathway (189) occurs with a half life of 1 ½
hours in atmospheric O2 (145), suggesting continuous production of the enzyme is
necessary to enable this prolonged NO production. For the experiments described herein,
we chose to investigate the effects of acute hypoxia at 24 hours after LPS and IFNγ
stimulation of RAW 264.7 cells, a macrophage-like transformed cell line, to ensure
robust and reproducible NO production.

Coexistence of Macrophage NO Production and Hypoxia in vivo
Molecular O2 is a cosubstrate for NO production (148, 155), thus the partial
pressure of oxygen (pO2) has the potential to affect macrophage function in vivo.
Physiological tissue pO2 measurements are 5 to 71 Torr (23, 32, 37, 42, 87, 88, 124, 129,
3

159, 253, 254, 263, 266, 281, 282), indicating that even in the absence of hypoxia (pO2 <
the normal pO2 for the tissue), macrophages are exposed to a wide range of pO2.
Macrophages are exposed to hypoxia when tissue pO2 decreases due to cardiovascular
compromise and/or overwhelming metabolic demand, such as in the wound environment
(116, 194, 213, 236) and in multiple inflammatory diseases: sepsis (118, 122), cancer (37,
38, 69, 70, 79, 111, 166), hypoxia-mediated pulmonary hypertension (154, 225), hypoxic
brain injury (125, 196, 220), congenital heart defects (72), necrotizing enterocolitis (45),
sleep apnea (75, 119, 295), asthma (17, 132, 289), cerebrovascular stroke (160), and
atherosclerosis (28, 34, 43). Three examples will be discussed: wound healing, sepsis,
and cancer.
The pO2 measured in the center of the wound environment can be as low as 0 to 2
Torr (225). Wound healing is typically thought to occur in three stages: inflammation,
proliferation, and maturation (285). Consistent with this model, macrophages have been
shown to to express iNOS for the first 24 to 72 hours of healing, and to become the
predominant cell type within the wound on days 3 to 5 (211). iNOS knockout mice have
delayed wound healing, which can be improved with gene transfer of the human iNOS
gene via an adenoviral vector (293), indicating that the presence of iNOS influences
wound healing. Nitrite and nitrate, metabolites of NO, are increased in the wound fluid
isolated from a sponge model of wound healing during the first 24 to 48 hours (177).
However, hypoxia (~ 0 Torr) has been shown to limit wound macrophage NO production
in vitro, and to result in the redirection of L-arginine metabolism to arginase (7). Further
investigation of NO production by macrophages expressing iNOS in a hypoxic
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environment is required to better understand how macrophages produces NO during
wound healing.
Improper wound healing and bacterial invasion into systemic circulation can lead
to the development of sepsis, a systemic inflammatory response (36). The progression of
sepsis to acute respiratory distress syndrome (ARDS) and multiorgan failure (MOF) is
one of the most frustrating syndromes to treat in human and animal emergency rooms and
intensive care units due to the rapidity of its progression (within 24 to 48 hours), and to
the high mortality rate in this patient population (20 to 50% in humans, 60% in dogs) (24,
64, 76, 175, 185, 228, 248). Patients initially become locally hypoxic due to the
redirection of blood flow to the vital organs and increased metabolic demand, and
subsequently become systemically hypoxic due to circulatory and pulmonary collapse
(118). NO production by PAMPs stimulated macrophages has been implicated in this
progression (44, 252).
Excessive amounts of nitrosylated and nitrated proteins, markers of endogenous
NO production (91, 262), have been detected in urine, plasma, and affected organs from
septic patients (86, 89, 140, 197, 243). iNOS has been demonstrated to directly bind,
nitrosylate, and increase the activity of cycloxygenase-2, even in the presence of
oxyhemoglobin, an extracellular NO scavenger (137). Alternatively, some nitrated
proteins have impaired function e.g. surfactant protein A can no longer aggregate lipids
(101). The NO metabolite, peroxynitrite, inhibits oxygen consumption by alveolar type
II cells (113), and mediates pulmonary cell damage and death (90). The ensuing hypoxia
due to impaired pulmonary gas exchange is exacerbated by the concurrent circulatory
dysfunction due to macrophage NO production. iNOS has a Vmax that is 5 fold greater
5

than the Vmax for endothelial NOS (eNOS) and neuronal NOS (nNOS) (214). Thus, one
of the major mechanisms contributing to generalized vasodilatation and septic shock is
the larger amount of NO produced by macrophages in similar tissue microenvironments
as endothelial cells (118, 252).
Because of these negative effects of NO production, nonspecific NOS inhibitors
(i.e. inhibition of iNOS, eNOS, and nNOS) were tested in animal models of sepsis (55,
77, 133-135, 183, 198, 244, 256, 257), and in human Phase I (97, 117), II (21, 272), and
III (167) clinical trials. Although effective in preventing the decrease in blood pressure
observed due to septic shock (21, 55, 97, 133-135, 167, 244, 272), in the Phase III
clinical trial patient mortality was ultimately increased, and the trial was terminated prior
to completion (167). Specific inhibitors of iNOS have been shown to have some benefit
in animal models (151, 161, 176, 199, 221, 249). However, bacterial sepsis in iNOS
knockouts results in increased mortality (54), or no survival advantage (152, 193),
probably due to the role of macrophage NO production in innate and adaptive immunity
(6, 94, 96, 215, 265). Thus, even specific inhibition of iNOS needs to be carefully
evaluated for its utility in treating septic patients. Macrophage NO production may
already be limited due to the tissue hypoxia, and more information is needed to enable the
development of NO targeted therapeutic strategies for sepsis.
A third example of macrophage exposure to hypoxia is within tumors. Hypoxia
has been documented in 50 to 60% of all solid tumors (166), and has been shown to
correlate with poor clinical outcome (37, 38, 69, 70, 79, 111, 166). Chronic
inflammation has been linked to the development of cancer (162), and while tumor
associated macrophages (TAM) are predominantly thought to have an M2 phenotype,
6

they have been demonstrated to express iNOS (235). Tumor cells themselves can also
express iNOS (12, 104, 261), and increased serum nitrite and nitrate levels correlated
with poor survival in lung cancer patients (56). However, some studies have shown that
NO can inhibit tumorigenesis and metastasis, and whether NO is beneficial or detrimental
has been proposed to depend on the location, degree, and timing of NO production (283,
284).
Anti-tumorigenic properties of NO include inhibition of mitochondrial respiration
(65, 246) and the induction of apoptosis (103, 173). Pro-tumorigenic properties include
genotoxic effects (71), increased iron uptake (66, 106, 255), promotion of angiogenesis
(12, 261), and promotion of tumor growth and metastasis (50, 83, 207, 291). The p53
status of the tumor is one mechanism which appears to determine whether NO is pro- or
anti-tumorigenic. p53 positive tumor cells typically undergo apoptosis due to NO
exposure, whereas p53 negative cells have increased VEGF production, resulting in the
promotion of angiogenesis (283).
In normoxic cells, NO increases VEGF production via HIF-1α stabilization, DNA
binding, and transcriptional activity (138, 204, 222, 223). However, in hypoxic cells, NO
decreased HIF-1α stabilization and HIF-1 activity (3, 114, 165, 238, 269), suggesting the
presence of hypoxia can affect the pro- versus anti-tumorigenic status of NO. Hypoxia
also stimulates VEGF production via HIF1 activation (15, 231, 274) and increases iron
uptake (51, 255). A better understanding of the hypoxic effects on macrophage NO
production is needed to elucidate how hypoxia and NO interact and contribute to cancer
development and progression.
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In summary, NO producing macrophages are exposed to a wide range of pO2, and
the requirement of molecular O2 for NO production (148, 155) suggests that tissue pO2
has the potential to influence macrophage NO generation. The presence of macrophage
NO production is a double edged sword for most diseases: some effects are beneficial
while others are detrimental to the host. The affect of macrophage NO production on
patient outcome (quality of life, and life vs. death) often seems to depend on the location,
timing, and degree of NO production, all of which will be affected by tissue pO2. Thus,
understanding the effects of pO2 on macrophage NO production is essential to
understanding the pathogenesis of multiple diseases.

Hypoxic Affects on NO production and iNOS in vitro
The effect of hypoxia on iNOS activity has been investigated in numerous models
(1, 2, 13, 46, 67, 110, 136, 179, 182, 202, 214, 296). Consistent with the role of
molecular O2 as a cosubstrate (148, 155), NO production uniformly was decreased during
hypoxia. However, the degree and duration of hypoxia required for this decrease, and the
mechanisms mediating this effect, have not been clearly defined.
The apparent KmO2 for isolated iNOS has been reported to be 6.3 ± 0.9 µM (5 ±
0.6 Torr) (214), 130 µM (93 Torr) (1), and 135 µM (96 Torr) (67). There are three
possible mechanisms explaining the differences between the studies: 1) the source of
iNOS, 2) the method of measurement, and 3) the method of pO2 control. When NO was
scavenged with oxyhemoglobin, the apparent KmO2 was reduced approximately 4 fold
from 130 µM (93 Torr) to 42 µM (30 Torr) (1). Abu-Soud et al. propose that the removal
of NO feedback inhibition by the scavenging of NO with oxyhemoglobin mediates the
8

shift they measured in the apparent KmO2 (1, 247). However, details regarding the
contribution of additonal O2 by oxyhemoglobin, a factor which could also cause a shift
toward a lower apparent KmO2, are not available.
The apparent KmO2 in stimulated macrophages has been investigated in two
studies. In one study, nitrite was measured following treatment with LPS and IFNγ for
24 hours at various pO2, and a calculated apparent KmO2 of 10.8 ± 2.0 % (77 ± 1.4 Torr)
was reported (179). Under similar culture conditions, Otto and Baumgardner measured a
hypoxia mediated decrease in iNOS activity at the conclusion of the exposure period (18
hours) via the citrulline assay in cell lysates at atmospheric O2, suggesting an effect of
pO2 on the specific activity and/or the amount of active iNOS, in addition to reactant
limitation (202). After normalizing nitrite production for changes in iNOS activity, and
accounting for the O2 diffusion gradient from the headspace gas to the cell surface, their
estimate for the apparent KmO2 at the cell surface was 14 Torr (202). Thus, the reported
apparent KmO2 for iNOS spans a wide range (5 Torr to 96 Torr), making it difficult to
assess which pO2 could regulate NO production in vivo.
The duration of hypoxia required for decreased macrophage NO production has
not been previously investigated. Prior studies relied on indirect measurement of NO
after 18 to 24 hours of concurrent exposure to LPS, IFNγ, and hypoxia (179, 202).
Therefore, the effects of hypoxia on iNOS upregulation could not be separated from the
effects due to reactant limitation. The amount of active iNOS, and the iNOS velocity,
during the 24 hour period may vary tremendously because of hypoxic effects on iNOS
mRNA, iNOS protein concentration, iNOS dimerization, and reactant availability.
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Hypoxic induction of iNOS is mediated by the transcription factor, HIF-1 (126,
205). HIF-1 is a dimer composed of HIF-1α and HIF-1β subunits. Both subunits are
constitutively expressed in most tissues (280). However, the HIF-1α protein is rapidly
degraded via the ubiquitin-proteosome pathway in the presence of O2 (59, 229, 230).
Hypoxia increases HIF-1 DNA binding to the iNOS hypoxia responsive element (HRE),
which upregulates iNOS transcription (126), (205). Upregulation of iNOS in rat primary
cardiac myocytes was measured at 12 hours (126). In contrast, hypoxic exposure
durations ≤ 24 hours did not increase iNOS mRNA in the CRL-2192 alveolar
macrophage cell line or in rat lungs (4). Exposure of rats to hypoxia (10% inspired pO2)
for 3 weeks increased iNOS mRNA in the lung (147, 198). These results suggest the
temporal effects of hypoxia on iNOS mRNA depends on the cell type. Co-stimulation of
CRL-2192 alveolar macrophages with LPS or IFNγ and hypoxia, or treatment of rats with
LPS immediately prior to hypoxia (9% inspired pO2), expedited the upregulation of iNOS
mRNA in the macrophages and in the lung, respectively, with an observed effect as early
as 3 hours (4).
Hypoxic upregulation of iNOS mRNA has not always resulted in increased iNOS
protein concentration. iNOS protein was decreased in LPS, IFNγ, and hypoxia stimulated
RAW 264.7 cells (24 hours (202)), and in TNFα, IL1β, and hypoxia stimulated rat
pulmonary artery cells (296). In contrast, iNOS protein was increased in LPS or IFNγ
and hypoxia stimulated CRL-2192 macrophages (4) and ANA-1 macrophages (182), and
in the lungs of rats treated with LPS, and then with 3, 6, or 12 hours of hypoxia (9% O2)
(4). Rats maintained in hypoxia (10% O2) for 3 weeks were also shown to have increased
iNOS protein in their lungs (154). Thus, the degree and duration of hypoxia, cytokine
10

concentration, combination of cytokines, and/or cell type appear to determine whether
upregulated iNOS mRNA correlates with increased iNOS protein concentration.
Following the upregulation of iNOS mRNA and protein expression, dimerization
is necessary for NO production (20). Dimerization requires BH4 (20, 147, 209, 260,
275), heme (20, 239), and L-arginine (20). Preliminary data in our laboratory measured a
decrease in the iNOS dimer:monomer ratio in RAW 264.7 cells costimulated with LPS,
IFNγ, and hypoxia (24 hours), which was fully reversible by L-sepiapterin, a
pharmacologic source of BH4 (201). Cytokine stimulation increases macrophage BH4
concentration via increased activity of the rate limiting enzyme, GTP cyclohydrolase I
(85, 276-278). Thus, these preliminary results suggest hypoxia may limit BH4
availability despite increased activity of GTP cyclohydrolase I.

Hypoxic Affects on NADPH and L-arginine availability
In addition to O2 substrate limitation, hypoxia has been reported to affect NADPH
and L-arginine availability. NADPH is produced by the oxidative pentose phosphate
cycle (OPPC) in LPS and IFNγ stimulated macrophages (58). An association between
NADPH production by glucose 6 phosphate dehydrogenase (G6PD), the rate limiting
enzyme of the OPPC, and NO production has previously been demonstrated in
macrophages (57, 112, 180, 258), and pharmacologic inhibition of OPPC activity or
G6PD deficiency was shown to significantly impair NO production (112, 180, 258).
Classical studies have measured increased [NADPH] in response to short term hypoxia
due to the absence of oxidizing agents (99, 127, 227, 259). More recently, however,
decreased [NADPH] was measured in denuded bovine coronary arteries following brief
11

exposure to hypoxia (~ 8 to 10 Torr, 20 minutes (100)). The effect of hypoxia on
macrophage OPPC activity and [NADPH] has not been investigated.
The concentration of L-arginine in cell culture media (JBMEM: 300 µM, MEM:
700 µM) is well above the apparent Km for arginine (2.8 µM; (245)), and is not expected
to be limiting for these studies. In addition, LPS and hypoxia increase the mRNA of the
arginine transporter, MCAT-2B (169), suggesting cellular L-arginine import is increased.
However, hypoxia (24 hours) alone and in combination with LPS has also been shown to
upregulate macrophage arginase (7, 169), which has been proposed to compete with
iNOS for L-arginine as a substrate (48, 108, 250). Inhibition of arginase can increase NO
production by stimulated macrophages, and vice versa (109). However, the interplay
between iNOS and arginase is cell specific (226), cytokine specific (107, 270), and time
dependent (270).

Specific Aims
In summary, hypoxia has the potential to alter macrophage NO production by
multiple mechanisms. Due to the difficulties of culturing cells at defined pO2, and the
difficulties of measuring NO production directly, previous studies were not able to
evaluate the effects of an abrupt change in pO2 on NO production. Therefore, the first
aim of this work was to measure macrophage NO production directly, and in real time,
during precise and accurate step changes in pO2 using a novel forced convection cell
culture system (Chapter 1). A decrease in NO production could be mediated by
limitation of the reactant(s) or an effect on iNOS itself. Limitation of molecular O2 is the
most intuitive mechanism. However, hypoxic exposure has also been documented to
12

affect the amount of active iNOS, and the availability of NADPH and L-arginine.
Therefore, the second specific aim of this work was to investigate the contribution of
these alternate mechanisms to the regulation of NO production during acute hypoxia
(Chapters 1, 2, and 3).

13

CHAPTER 1.
PHYSIOLOGICAL AND HYPOXIC O2 TENSIONS RAPIDLY REGULATE NO
PRODUCTION BY STIMULATED MACROPHAGES

Mary A. Robinson1,2,3, James E. Baumgardner4,5, Virginia P. Good2, and Cynthia M. Otto1,2,
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ABSTRACT
NO production by inducible nitric oxide synthase (iNOS) is dependent on O2
availability. The duration and degree of hypoxia which limit NO production are poorly
defined in cultured cells. To investigate short term O2-mediated regulation of NO
production, we used a novel forced convection cell culture system to rapidly (response
time = 1.6 seconds) and accurately (± 1 Torr) deliver specific O2 tensions (from < 1 to
157 Torr) directly to a monolayer of LPS and IFNγ stimulated RAW 264.7 cells while
simultaneously measuring NO production via an electrochemical probe. Decreased O2
availability rapidly (≤ 30 seconds) and reversibly decreased NO production with an
apparent KmO2 of 22 (SD 6) Torr (31 µM) and a Vmax of 4.9 (SD 0.4) nmol/min·106 cells.
To explore potential mechanisms of decreased NO production during hypoxia, we
investigated O2-dependent changes in iNOS protein concentration, iNOS dimerization,
and cellular NO consumption. iNOS protein concentration was not affected (p = 0.895).
iNOS dimerization appeared to be biphasic (6 Torr (p ≤ 0.008) and 157 Torr (p ≤ 0.258)
> 36 Torr), but did not predict NO production. NO consumption was minimal at high O2
and NO tensions and negligible at low O2 and NO tensions. These results are consistent
with O2 substrate limitation as a regulatory mechanism during brief hypoxic exposure.
The rapid and reversible effects of physiological and pathophysiological O2 tensions
suggest that O2 tension has the potential to regulate NO production in vivo.
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INTRODUCTION
Macrophage NO production via inducible nitric oxide synthase (iNOS) is a key
component of the cellular inflammatory response (33, 172). In vivo, in vitro, and isolated
enzyme experiments have clearly demonstrated the dependence of NO production on O2
tension for all 3 of the NOS isoforms (1, 2, 13, 46, 67, 110, 136, 179, 182, 202, 214,
296). Normal non-pulmonary tissue O2 tensions range from 5 to 71 Torr (23, 37, 42, 124,
129, 263, 282), and systemic and/or tissue hypoxia develops during several inflammatory
diseases (42, 75, 122), extending the range for tissue macrophages to even lower levels.
Alveolar macrophages can be exposed to O2 tensions ranging from approximately 30
Torr (mixed venous O2 tension with atelectasis) to over 650 Torr (with O2 therapy) (279).
Thus, macrophages must function over a wide range of physiologic and
pathophysiological O2 tensions, and O2 tension has the potential to regulate macrophage
NO production (67, 179, 202, 214). It is currently unknown, however, if the macrophage
response to changing O2 tension is rapid enough for O2 to play a role in the regulation of
NO production.
Prior studies have explored the long-term effects (18 and 24 hours) of culture PO2
(partial pressure of O2) on nitrite production in LPS and IFNγ stimulated RAW 264.7
cells, but estimates of the apparent KmO2 have varied considerably. McCormick et al.
reported an apparent KmO2 of 10.8% (77 Torr) for the PO2 in the headspace gas (179). In
contrast, Otto and Baumgardner estimated the apparent KmO2 at the cell surface to be 14
Torr, after normalizing to iNOS activity and accounting for the O2 diffusion gradient
through the media layer (202). This wide range of reported KmO2 may be in part due to
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difficulties in accurately controlling headspace (202, 242) and cellular (22, 202) PO2 in
conventional cell culture.
No prior studies of macrophage NO production explored the effects of short-term
exposure to different O2 tensions, primarily due to the limitations of conventional cell
culture and NO analysis methods. First, diffusion of O2 through the media covering cells
cultured in dishes can be slow, requiring as long as 30 minutes for a change in headspace
PO2 to be translated to the cell surface (10, 22). Second, the sensitivity of nitrite
measurement via the Griess method, which integrates NO production over the period of
the experiment, is not adequate for short time periods with less NO accumulation (121,
179, 202).
Forced convection cell culture utilizes a continuous flow of media to deliver O2
and nutrients directly to the cell monolayer, and to remove waste products (22). Because
this method of cell culture overcomes the limitations of extracellular O2 diffusion, it is
ideally suited for measuring the effects of rapid changes in O2 tension. In addition, the
system used for the present study controls O2 tensions with an accuracy of about 1 Torr,
and permits rapid, direct measurement of changes in NO in the effluent using a sensitive
electrochemical probe (216, 217). Thus, the first goal of our current study was to use this
recently developed method to accurately define the PO2 dependence of NO production by
LPS and IFNγ stimulated RAW 264.7 cells, after brief exposures to a range of
physiological and hypoxic O2 tensions.
The second goal of our study was to evaluate three mechanisms that could alter
NO production after brief hypoxic exposures. The oxygen atom in NO is derived from
molecular O2 (148, 155). Prior cell culture studies which used long term exposures to
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varying O2 tensions, and studies with isolated nitric oxide synthases (NOS), have
emphasized the potential role of O2 as a rate-limiting substrate (67, 179, 202, 214). O2
has also been shown to participate in more complex interactions with the NOS enzyme
than simple substrate dependence (247). These mechanisms could operate on a short
enough time scale to alter NO production after brief hypoxic exposures. There are,
however, several additional opportunities for changes in PO2 to rapidly influence NO
production. Our goal was to evaluate three of these additional mechanisms: changes in
the cellular levels of inducible NOS (iNOS) protein, changes in iNOS dimerization, and
changes in cellular NO consumption. We hypothesized that: 1) brief hypoxic exposures
would reduce NO production by reducing iNOS protein; 2) brief hypoxic exposures
would reduce NO production by reducing iNOS dimerization; and 3) brief hypoxic
exposures would reduce NO production and release from the cell by increasing
intracellular consumption of NO.

MATERIALS AND METHODS
Forced Convection Cell Culture.
RAW 264.7 cells (American Type Culture Collection, Manassas, VA) were
cultured using a novel forced convection cell culture system as described previously (22).
Briefly, cells were aspirated through a ProNectin® F-coated (0.1mg/ml; Sigma, St Louis,
MO) 0.53 mm diameter, 10 cm long fused-silica capillary column (Alltech, Deerfield,
IL), allowed to adhere for 15 minutes, and cultured with forced convection in air with 5%
CO2 for 18 to 22 hours in the presence of 1 µg/ml LPS (E. coli O111:B4; Sigma) and 100
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U/ml CHO-derived recombinant mouse IFNγ (Cell Sciences, Canton, MA) in DMEM
(Gibco, Carlsbad, CA) supplemented with 5% heat-inactivated FBS (LONZA, Visp,
Valais, Switzerland) and 1% antibiotic/antimycotic (penicillin, streptamycin, fungizone;
Life Technologies, Gaithersburg, MD). Following stimulation, the column of cells was
transferred to the forced convection cell culture system (Figure 1).
Experiments were performed in a minimal essential media (JBMEM: 140 mM
NaCl, 1.4 mM CaCl2, 5.3 mM KCl, 4.4 mM Dextrose, 25 mM HEPES, 0.3 mM Larginine, and 0.1% heat-inactivated FBS (LONZA)) equilibrated with 0, 0.7, 3.6, 8.4,
15.2, 25.8, 38.0, 85.3, or 159.6 Torr O2 (5% CO2, balance N2) from certified premixed
compressed gas cylinders (AirGas, Allentown, PA). Corresponding estimates of average
cellular PO2, after accounting for cellular O2 consumption, were 0, < 1, 1, 6, 13, 24, 36,
83, or 157 Torr O2 (22). Upon completion of experiments, the fluid was briefly switched
to PBS equilibrated with the experimental O2 tension, and then the column of cells was
removed from the system and immediately frozen at -70°C.

Measurement of Effluent NO Tension.
NO was detected using a 2 mm NO electrode (NOP, World Precision Instruments,
Sarasota, FL) filled with a CO2 insensitive electrolyte (World Precision Instruments). To
enable calibration of the NO electrode, the forced convection cell culture system was
adapted to allow defined amounts of NO (input NO) to be added to the fluid stream
(Figure 1). Deionized H2O (dH2O) was deoxygenated via a membrane equilibrator with
certified ultra high purity N2 (AirGas), then equilibrated via a second membrane
equilibrator with 2000 ppm NO in N2 (AirGas). As in our prior report (6), function of all
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membrane equilibrators was tested by confirming flow independence of the measured gas
partial pressure in the equilibrator effluent. Defined amounts of 2000 ppm NOcontaining dH2O were injected into the fluid stream using a syringe pump (Harvard
Apparatus, Holliston, MA). The electrode was calibrated with input PNO of 19, 40, 79,
160, 319, and 500 ppm at the beginning of each day. In the forced convection system,
the measured 0-95% time constant for the probe was 27 seconds. Due to NO probe
baseline drift during experiments, the NO probe baseline was measured regularly (i.e. ≤ 5
minute intervals) to allow for manual baseline correction of the data.
All NO measurements were performed in JBMEM, which was designed to
minimize media NO consumption while maintaining cell viability. To evaluate NO
consumption by JBMEM, the forced convection system depicted in Figure 1 was
modified by inserting two lengths of fused silica (13 cm and 30 cm) between the NO
input site (labeled T in Figure 1) and the outlet valve (labeled B in Figure 1), resulting in
exposure of NO to the media for 9 and 18 seconds, respectively. The NO signal was
recorded for each exposure duration at two input PNO (160 and 320 ppm), and at three PO2
(0, 40 and 80 Torr). PO2 dependence of NO consumption in JBMEM was further
investigated after restoring the system to the configuration of Figure 1 (i.e. 16 cm of
tubing between the NO input and the inlet valve, labeled A in Figure 1, and 10 cm of
tubing between the inlet valve and the outlet valve) in the absence of cells at five PNO (40,
79, 160, 319, 500 ppm) and six PO2 (0, 15, 26, 38, 85, 160 Torr). To test if JBMEM was
sufficient to support cell viability, RAW 264.7 cells were seeded onto 6 well plates (9.5
cm2) and cultured in a humidified incubator (room air, 37°C, 5% CO2) in either DMEM
or JBMEM. Viability was measured by Trypan blue staining after 2, 6 or 18 hours of
20

culture. Cells were evaluated with and without stimulation (1 µg/ml LPS and 100 U/ml
IFNγ initiated 18 hours prior to seeding).

Electrophoresis and Immunoblotting.
Cell lysates were prepared from columns by aspirating ice cold protease-inhibitor
containing hypotonic lysis buffer (PIB: 10 µM phenylmethylsulfonyl fluoride (ICN
Biochemical, Aurora, OH), 5 µg/ml aprotinin (Sigma), and 5 µg/ml pepstatin (Amresco,
Solon, OH) in dH2O) through each column. Cell lysate protein concentrations were
measured using the Biorad DC protein assay (Hercules, CA).
Proteins (10 µg) were separated on a 7.5% Tris-HCl gel using SDS PAGE or low
temperature SDS PAGE (LT SDS PAGE) as previously described (287), except the final
β-mercaptoethanol concentration for samples subjected to LT SDS PAGE was 0.1%
(v/v). Proteins were transferred to polyvinylidene fluoride (ImmobilonTM-FL 0.2µm;
Millipore, Bedford, MA) and immunoblotted for iNOS (1:1000 to 1:2000; NOS2 M19
sc650, Santa Cruz Biotechnology, Inc., Santa Cruz, CA) and the loading control, Raf-1
(1:200 to 1:500; Raf-1 sc227, Santa Cruz Biotechnology, Inc.). Primary antibodies were
immunocomplexed with IRDyeTM 800 goat anti-rabbit (1:20,000; Rockland, Gilbertsville,
PA). Proteins were detected, documented, and analyzed using an Odyssey Imaging
System and software (LiCor Biosciences, Lincoln, NE).

Cellular NO Consumption.
Endogenous NO production by LPS and IFNγ stimulated RAW 264.7 cells
cultured in the forced convection system was inhibited by a 36 to 48 minute exposure to
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100 µM N-[[3-(aminomethyl)phenyl]methyl]-ethanimidamide, dihydrochloride (1400W;
Cayman Chemical, Ann Arbor, MI) in JBMEM lacking L-arginine. Maximal NO
inhibition by 1400W (86 SD 7 % of basal NO production; n = 8), was expedited by 3 to 4
periods of stopped flow for 5 minutes followed by 7 minutes of flow. Once maximal
inhibition of endogenous NO production was achieved, cells were returned to JBMEM
with L-arginine and were sequentially exposed to input PNO of 40, 79, 160, 319, 500, and
0 ppm in the presence of 6, 36, or 83 Torr O2. Average effluent PNO was recorded for
each input PNO once steady state was achieved, and was compared to average effluent PNO
recorded on the same day for the same input PNO in the absence of cells. The difference
between effluent PNO with cells and without cells for each input PNO was assumed to be
due to the net result of NO consumption and residual endogenous NO production.
Testing for zero order, first order, or higher order dependence of NO consumption on PNO
and PO2 was performed, and the data were analyzed, by considering a mass balance on
the cell column:

(NO entering the column) – (NO leaving the column) = consumption – production

Production represents the small amount of residual cellular NO production that was not
inhibited by 1400W treatment. Consumption represents overall cellular degradation of
NO from all irreversible and slowly reversible reactions, for example reaction with
superoxide to form peroxynitrite (30, 115), conversion to nitrate via the iNOS futile
pathway (247), nitrosylation, nitration and oxidation of proteins (92), autoxidation (74,
164), and other reactions (74, 212).
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Our analysis assumes that NO production is independent of NO concentration,
since the range of NO concentrations we studied is below the range associated with NO
feedback inhibition of inducible nitric oxide synthase (iNOS) (1). Consumption is
modeled, as a starting point, as first order in both NO and O2 (251). It is known that
autoxidation is second order in NO and first order in O2 (74), but the reaction is too slow
to consume NO before it reaches the electrode. Additionally, our data were calibrated to
the effluent PNO detected for the five input PNO in JBMEM in the absence of cells and O2.
Therefore, the detected NO consumption in our experiments is expected to be dominated
by intracellular consumption reactions. The mass balance on the column of cells
becomes

QαNO(PNOi-PNOe) = kcN (PO2)(PNO) – f(PO2)kpN

Where:

Q is the media flow rate through the column (4.27x10-6 L/sec)
αNO is the NO solubility in media at 37°C (2.13x106 pM/Torr) (271)
PNOi is the NO partial pressure in media entering the column (Torr)
PNOe is the NO partial pressure in media leaving the column (Torr)
kc is the consumption rate constant (pmol NO/ cell·sec·Torr2)
PO2 is the average oxygen partial pressure for cells in the column
PNO is the average NO partial pressure for cells in the column
f(PO2) is the functional dependence of NO production on PO2
kp is the maximal NO production for each column at high PO2 (pmol NO/
cell·sec)
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N is the number of cells in the column
Statistics.
Comparison of means were tested by a one way ANOVA for each PNO for PO2
dependent NO consumption in the absence of cells (Figure 2), a two way ANOVA for the
effects of DMEM versus JBMEM over time on cell survival (Table 2), and a three way
ANOVA for the effects of input PNO, PO2 and exposure time on NO degradation in
JBMEM using SigmaStat version 3.1. All other statistics were performed using
GraphPad InStat version 3.06 for Windows 95, GraphPad Software, San Diego, CA,
www.graphpad.com. Changes in NO production with repeated cycling between 0 and 36
Torr O2 (Figure 3A) were tested by linear regression. The apparent Km and Vmax were
calculated by SigmaPlot Enzyme Kinetics Module 1.1 using a Michaelis-Menten nonlinear analysis (Figure 3C). Comparison of means for iNOS protein concentration data
(Figure 4) were tested by one-way ANOVA. Comparison of means for iNOS
dimerization data (Figure 5) were tested by pair-wise t-tests with a Bonferroni correction.
Testing of the NO consumption model was performed with linear regression as described
in Appendix A.
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RESULTS
Characteristics of JBMEM.
In the absence of O2 and cells, NO was rapidly consumed in DMEM by many of
its components (Table 1), consistent with previous reports(39, 47, 131). Consumption of
160 and 320 ppm NO in JBMEM was investigated in the absence of cells at 0, 40, and 80
Torr O2 by varying exposure duration. Exposure duration (9 versus 18 seconds) and PO2
had no effect on the measured NO signal (n ≥ 2; p = 0.516 and p = 0.201, respectively),
indicating negligible consumption by the media for exposures less than 18 seconds.
Consistent with these observations, PO2 dependent NO consumption in JBMEM was not
detectable for any of the input PNO investigated with the system in its standard
configuration as depicted in Figure 1, with a 15 second transit time from the NO input to
the NO electrode (Figure 2; n = 3; 500 ppm, p = 0.152; 319 ppm, p = 0.264; 160 ppm, p =
0.370; 79 ppm, p = 0.951; 40 ppm, p = 0.468). For all subsequent experiments, NO
consumption during the approximately 3.5 second average transit time from the cells to
the NO electrode was therefore considered negligible.
In unstimulated cells, there was a small but significant reduction of cell viability
with JBMEM (Table 2; p = 0.028). There was no detectable effect of time (p = 0.074) or
interaction between media type and time (p = 0.601). In cells cultured with LPS and
IFNγ, no significant effect of media (p = 0.364) or time (p = 0.894) was detected.

Effect of O2 tension on effluent PNO.
Steady-state NO release by LPS and IFNγ stimulated RAW 264.7 cells exposed to
36 Torr O2 was 3.08 (SD 1.14) nmol/min·106 cells (n = 5). Unstimulated cells did not
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produce detectable NO (data not shown). Exposure of the cells to 0 Torr O2 decreased
effluent PNO within 30 seconds to an undetectable amount (Figure 3A). Similarly, within
30 seconds of re-exposure to 36 Torr O2, effluent PNO was greater than or equal to the
initial measured concentration. Repeated cycling between 0 Torr (2 minutes) and 36 Torr
O2 (3 minutes) consistently produced these rapid changes in effluent PNO with a
cumulative 10% increase in effluent PNO over a period of 40 minutes (p < 0.0001, n = 2).
Unstimulated cells subjected to identical cycling patterns between 0 Torr and 36 Torr O2
for 40 minutes did not produce detectable NO (data not shown).
Exposure of LPS and IFNγ stimulated RAW 264.7 cells to a range of O2 tensions
elicited corresponding changes in effluent PNO, which predominantly followed a
Michaelis-Menten kinetic model (Figure 3B). A non-linear analysis computed an
apparent KmO2 of 22 (SD 6) Torr and Vmax of 4.9 (SD 0.4) nmol/min·106 cells (n = 5, R2 =
0.80). A slight deviation from a smooth monotonic function is apparent between 6 and
36 Torr O2 (Figure 3C).

Effect of O2 tension on iNOS.
O2 tension did not influence iNOS protein concentration (Figure 4, n ≥ 4, p =
0.895), but did influence the bands thought to contain iNOS dimers (Figure 5, n = 3). In
the western blot derived from the partially denaturing gel, three bands were present: a
band corresponding to the expected monomer molecular weight (~130 kD) (49), a band
corresponding to the expected dimer molecular weight (~260 kD), and an unexpected
band of much higher molecular weight (≥ 500 kD). Compared to 36 Torr, the ratio of the
260 kD band to the 130 kD band was significantly increased in lysates from samples at 6
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Torr (p = 0.003). A similar finding was observed for the ratio of the 500 kD band to the
130 kD band (p = 0.008). The ratios also appeared to increase in lysates from samples at
157 Torr, but the increase did not achieve statistical significance (260 kD ratio p = 0.258,
500 kD ratio p = 0.129).

Effect of NO and O2 tension on cellular NO consumption.
Following 1400W inhibition of endogenous NO production (Figure 6A), LPS and
IFNγ stimulated RAW 264.7 cells at 6, 36, or 83 Torr O2 were exposed to five input PNO
(Figure 6B). Data are presented in Figure 6C as the ratio of effluent PNO with cells to
effluent PNO without cells. Net cellular NO consumption, as indicated by a ratio less than
1, was evident at input PNO of 160, 319, and 500 ppm in PO2 of 36 and 83 Torr.
Calculations based on known autoxidation rate constants (74, 164) estimated that
autoxidation within the cells could account for a maximum of 3% of the measured NO
consumption. Cellular consumption was negligible at a PO2 of 6 Torr, regardless of the
input PNO. Net cellular NO production resulted in a ratio greater than 1 for the lower two
input PNO (40 and 79 ppm) delivered in the lower two PO2 (36 and 83 Torr). The amount
of NO production was consistent with the residual cellular NO that was not inhibited by
1400W. Immediately following 1400W treatment, mean cellular NO production was
14% (SD 7) (n = 8) of initial NO production. By the end of the experiment, cellular
production increased to 24% (SD 6) (n = 7) of initial NO production. The relationship
between net cellular NO consumption and PNO was most consistent with 1st order kinetics.
NO consumption also correlated positively with PO2 in a 1st order-dependent manner at
all PNO. The overall consumption constant (kc) for the model was 0.038 pmol NO/sec·106
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cells·Torr2 [12.7 (mmol NO)/(sec·106 cells·M2)]. Details of the consumption model are
presented in Appendix A.
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DISCUSSION
Our study examined the effects of brief exposures to O2 tensions, ranging from <
1 Torr to 157 Torr, on the production and release of NO by stimulated macrophages.
Decreased PO2 rapidly and reversibly decreased NO production, with an apparent KmO2
of 22 (SD 6) Torr. Short term hypoxic exposures did not affect iNOS protein levels, but
did influence iNOS dimerization. Surprisingly, however, iNOS dimerization did not
predict NO production. NO consumption was small at high cellular O2 and NO tensions
and was negligible at low O2 and NO tensions.
Our measured apparent KmO2 is within the range of values reported previously for
long term exposures in macrophage cell culture (179, 202), and for the isolated iNOS
enzyme (1, 67, 214). It is also well within the range of PO2 that would be required for O2
tension to regulate NO production in vivo, as has been suggested previously (1, 67, 179,
202, 214). Our study additionally demonstrated, however, that precisely controlled
changes in extracellular O2 tension altered NO production by intact isolated cells within
seconds, and that this effect was immediately reversible. A slow response, or an
irreversible response, would have argued against any role for the regulation of NO
production by PO2 changes in intact cells. Instead, the effect on cellular NO production
was rapid and reversible, further supporting a significant regulatory role for O2 tension in
vivo.
Several studies have investigated PO2 dependence of NO production in intact
tissues, and in vivo. NO production has been shown to be rapidly decreased by hypoxia
when the primary enzyme responsible for NO production was thought to be endothelial
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NOS (eNOS) (110, 136), iNOS (67), or neuronal NOS (nNOS) (292). O2-mediated
intracellular kinetics and regulatory mechanisms, however, are difficult to evaluate in
vivo and in tissue models due to the complications of tissue structure and O2 delivery
dynamics. Tissues are by definition composed of several different cell types with the
potential for expression of several different NOS isoforms, and it is often difficult to
unequivocally define which isoform is primarily responsible for producing the measured
NO. For example, in bronchial airways each isoform is expressed in different cells (35,
67), and in different regions of the same cells (35, 290). This could have important
effects on total NO production, as the KmO2 for each isoform varies markedly in isolated
enzyme studies (1, 214). Although tissue and in vivo studies are not directly comparable
to our cell culture study, they do support the concept that NO production can be rapidly
regulated by changes in O2 tension in vivo.
We are not aware of any prior cell culture studies of NO production during brief
exposure to hypoxia for the direct comparison to our results. Two prior studies, however,
investigated the effects of long term exposure ( ≥ 18 hours) to multiple O2 tensions on
nitrite production by RAW 264.7 cells concurrently stimulated with LPS and IFNγ (179,
202). McCormick et al. measured cellular nitrite production following 24 hours of
exposure to various headspace O2 tensions ranging from 1% to 21% (7 to 150 Torr). The
decrease in nitrite production at low O2 tensions was well described by a hyperbolic
curve fit, and the apparent KmO2 for the headspace gas was 10.8% (77 Torr) (179). Otto
and Baumgardner measured cellular nitrite production following 18 hours of exposure to
various headspace O2 tensions ranging from 1 to 677 Torr. Nitrite production decreased
with decreasing O2 tension throughout the entire range. iNOS activity in cell lysates,
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defined by citrulline production in room air at 25°C, also showed substantial dependence
on cellular PO2 prior to lysis, suggesting an effect of O2 tension on specific activity
and/or the amount of active iNOS. After normalizing nitrite production for changes in
iNOS activity, and accounting for the O2 diffusion gradient from the headspace gas to the
cell surface, their estimate for the apparent KmO2 at the cell surface was 14 Torr (202).
Studies of long term exposures to different O2 tensions are not strictly comparable to the
short term exposures of the current study due to the many factors that could change
slowly over time. For example, O2 dependent changes in the transcription and translation
of iNOS (4, 126, 179, 181, 182, 202), as well as of other relevant proteins (e.g. mediators
of arginine metabolism (169)), would be expected to take several hours (4) and could
substantially influence NO production in long term exposures, yet have minimal impact
in short term exposures.
Three prior studies have investigated the apparent KmO2 for isolated iNOS. Using
a steady state kinetics approach, Rengasamy and Johns measured citrulline production at
various PO2 by iNOS within a RAW 264.7 cell lysate. In their system, O2 tension was
rigidly controlled in the headspace gas by use of continuous gas flows, and the reaction
mixture was constantly stirred to minimize diffusion gradients. They reported an
apparent KmO2 for iNOS of 6.3 µM, for a solution temperature of 37°C (214). Using a
rapid equilibrium kinetics approach, Abu-Soud et al. and Dweik et al. studied the effects
of O2 tension on purified recombinant mouse iNOS by measuring the rate of NADPH
oxidation spectroscopically, in a closed system at 25°C (1, 67). They reported an
apparent KmO2 of 130 µM (1) and 135µM (67). When the NO produced was scavenged
with oxyhemoglobin, however, the measured KmO2 was reduced approximately 4 fold to
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42 µM (1). The difference between these values was shown to be due to direct feedback
inhibition of iNOS by NO, an effect that has been demonstrated for all 3 NOS isoforms
(247).
In our experiments using forced convection cell culture, the flowing media
continuously removed NO as it was produced, thereby minimizing NO accumulation.
Our results, therefore, are most comparable to the isolated enzyme experiments that either
continuously removed NO with flowing headspace gas in an open system (Rengasamy
and Johns, KmO2 6.3 µM (214)), or scavenged NO with oxyhemoglobin in a closed
system(Abu Soud et al., KmO2 42 µM (1)). The apparent KmO2 we measured for intact
cells was 22 (SD 6) Torr (31 µM based on an Ostwald solubility coefficient of 0.0271 ml
O2 BTP/ml water-atm at 37°C (273)). Unlike the isolated enzyme, within intact cells
several mechanisms in addition to substrate dependence and product feedback inhibition
could acutely alter NO production after a change in PO2. We investigated 3 potential
mechanisms: changes in iNOS protein levels, iNOS dimerization, and cellular NO
consumption.
iNOS protein levels were not influenced by brief hypoxic exposures. Hypoxia
has been shown to induce increased expression of iNOS mRNA and protein via HIF 1αdependent regulation (126, 181, 182). Acute changes in PO2, however, would not be
expected to acutely increase iNOS protein production because transcription and
translation have been shown to take up to 6 hours to change after an appropriate stimulus
(4). To our knowledge, the effect of hypoxia on iNOS degradation has not been
investigated. The iNOS half life in room air, however, was approximately 1.6 hours in
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several cell types (145). Our results showing that brief hypoxic exposures have little
impact on iNOS protein are consistent with these previous studies.
iNOS dimerization was influenced by brief exposure to various O2 tensions, but
surprisingly did not correlate with changes in NO production. The changes in
dimerization appeared to be biphasic (6 Torr and 157 Torr > 36 Torr), and were
consistent for the 260 kD band, the expected size for iNOS dimers (49), and for the 500
kD band, an undefined iNOS-containing protein complex. Our data for NO production as
a function of cellular O2 tension (Figure 3C), and data from a prior study on iNOS
activity as a function of O2 tension (202), show deviations from a smooth monotonic
function in that range of PO2, that may in part be related to the biphasic changes we
observed in dimerization. Decreased NO production despite a large increase in iNOS
dimerization during hypoxia could be due to O2 substrate limitation, limitation of another
substrate or cofactor during hypoxia, and/or the generation of inactive dimers.
Cellular NO consumption was negligible at all but the highest PO2 and PNO, with
an overall consumption constant of 0.038 pmol NO/sec·106 cells·Torr2 [12.7 (mmol NO)/
(sec·106 cells·M NO·M O2)]. There are many possible intracellular reactants that can
directly consume NO, and correspondingly, there are many possible reaction kinetics for
cellular NO consumption (93, 150, 212). Our data is most consistent with first order
dependence in NO and O2, most similar to the findings of Thomas et al. (251). Our
consumption rates are at the low end of the reported range for various cell types (0.050 to
1.61 pmol NO/sec·106 cells·Torr2) (81, 251), but are consistent with a previous report of
LPS and IFNγ stimulated RAW 264.7 cells (0.011 pmol NO/sec·106 cells·Torr2 (190);
see Appendix B for conversion of consumption constants to comparable units).
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In summary, we used a novel forced convection cell culture system to precisely
regulate cellular O2 tensions in the range of < 1 Torr to 157 Torr. In an LPS and IFNγ
stimulated macrophage cell line, decreases in cellular PO2 reduced NO production within
seconds, an effect which was immediately reversible with restoration of the original PO2.
The apparent KmO2 for this oxygen dependence was 22 (SD 6) Torr (31 µM). The
changes in NO production were not explained by the effects of cell PO2 on iNOS protein
levels, iNOS dimerization, or consumption of NO. The rapid effects of cellular PO2 on
macrophage NO production are consistent with regulation of NO production by O2
substrate limitation. The apparent KmO2 in intact cells and the kinetics of the PO2
dependence suggest that O2 substrate limitation could play a dynamic role in the
regulation of NO production by iNOS in vivo.
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APPENDIX A: NO Consumption Model
For each individual column, studied at a fixed PO2, QαNO(PNOi-PNOe) was plotted
against PNO (Figure S1) to assess for linear dependence that would indicate that first order
kinetics in NO are appropriate. The negative intercept on this plot is production, i.e.
intercept = -f(PO2)kpN, which could be of any functional form (for example the
Michaelis-Menten fit in Figure 3). The only assumption required about production for
this analysis of NO consumption is that the production is independent of PNO.
For the experiments at higher PO2 (36 and 83 Torr) in figure S1, a linear fit is
clearly adequate, and the slopes were significantly different from zero. At lower PO2, as
the slope of this relationship approaches zero, the power to detect a slope significantly
different from zero is reduced. As expected, the trend for a linear relationship did not
result in a slope significantly different from zero (p ≥ 0.122) for the PO2 = 6 Torr data
sets.
For each column, the best fit slope (b1) of the QαNO(PNOi-PNOe) versus PNO data was
divided by PO2 and plotted against PO2 (Figure S2). First order dependence in PO2
predicts that b1/PO2 should be independent of PO2. The data of figure S2 are consistent
with a constant b1/PO2 that is independent of PO2, confirmed by a best fit regression
slope not significantly different from zero (p = 0.422).
The best estimate of the overall consumption constant kcN was estimated from a
weighted average of the b1/PO2 values in figure S2 that accounts for the fact that the
confidence in parameter estimates is increased at higher PO2. The weighted average
assigned weights in direct proportion to PO2. The resulting best estimate for kcN was
0.0186 pmol NO/sec·Torr2.
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Finally, cell number for these experiments was estimated from representative
measurements of total protein after lysis of cells from the columns, combined with a
previously established relationship between cell number and protein for RAW 264.7 cells
(202):

N = -1.99x104 + 7.09x106(protein)

where protein is in mg. Average cell number for these experiments was 4.9x105.
The overall NO consumption rate constant, normalized to cell number, is

NO consumption = 0.038 (pmol NO)/(sec·106 cells·Torr NO·Torr O2)
= 12.7 (mmol NO)/(sec·106 cells·M NO·M O2)
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APPENDIX B: Conversion of kc Units for Comparison to Previous Studies
Thomas et al. reported NO consumption data for cultured rat hepatocytes (251).
NO consumption was first order in both NO concentration and O2 concentration, with a
rate constant of 5.38x10-4 M-1·sec-1·(cell/ml)-1. For an NO solubility at 37°C of 2.13 µM/
Torr (271) and an O2 solubility at 37°C of 1.40 µM/Torr (273), the equivalent rate
constant in units compatible with our reported value is 1.61 pmol/sec·106 cells·Torr2.
Nalwaya and Deen reported NO consumption data for stimulated RAW 264.7
cells (190). NO consumption was treated as first order in NO and zero order in O2, with a
rate constant of 0.6 sec-1. They measured NO consumption over a range of PO2. Taking
as an approximation a PO2 in the middle of this range at 100 Torr, with an NO solubility
as above, and with their estimate of cell volume of 8.8x10-13 L/cell, the equivalent rate
constant is 0.011 pmol/sec·106 cells·Torr2.
Gardner et.al. reported NO consumption data for several cell types (81). NO
consumption values, in compatible units, ranged from 0.050 to 0.52 pmol/sec·106
cells·Torr2.

37

Figure 1.

Forced convection cell culture system. Adherent RAW 264.7 cells were cultured at 37°C
on the inside of a fused-silica column (inset). The media, delivered by forced convection
via a roller pump, was partially degassed by prewarming to 40°C, and then was
equilibrated with calibrated compressed gas mixtures ranging from 0 to 157 Torr O2 (5%
CO2, balance N2) inside one of two gas equilibrators (labeled Gas Equilibrator 1 and 2).
Rapid changes in O2 tension or media components were enabled by a switching valve
upstream from the column of adherent cells (labeled A). NO in the media stream
(effluent NO) was measured by an NO electrode (WPI) located downstream from a
second switching valve (labeled B) that permitted assay of media from the cells or a
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bypass. The bypass loop allowed for regular electrode baseline measurements. A
syringe pump controlled the delivery of deoxygenated, deionized H2O equilibrated with
2000 ppm NO (balance N2) into a T connector (labeled T) inserted into the media stream
from gas equilibrator 2. The addition of specific NO tensions (input NO) enabled
calibration of the NO electrode and evaluation of cellular NO consumption. Figure
adapted from Baumgardner and Otto (6).
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Figure 2.

NO Consumption by Media. Oxygen dependence of the signal at the NO electrode was
measured as a function of NO tension in minimal essential media (JBMEM) in the
absence of cells. Each bar represents the mean (SD) of the NO probe signal (pA) for
JBMEM at five input PNO and six PO2 (n = 3). Because the conversion of NO to its stable
end products (NO2 and NO3) is O2 dependent, the results imply that NO consumption by
the media is negligible.
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Figure 3.

Effect of PO2 on NO Production. A. Representative tracing of NO (ppm) released by
LPS and IFNγ stimulated RAW 264.7 cells during rapid switching between 0 and 36 Torr
O2. Cells were repeatedly exposed to 0 Torr O2 for 2 minutes, then 36 Torr O2 for 3
minutes for a combined total of 40 minutes (n = 4). Arrows indicate probe baseline,
which was measured at the beginning and end of the experiments via the bypass loop. B.
Representative tracing from one of five experiments in which LPS and IFNγ stimulated
RAW 264.7 cells were exposed to eight O2 tensions ranging from < 1 to 157 Torr in a
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randomized order, while effluent NO (ppm) was measured electrochemically. In between
each O2 tension, cells were exposed to 0 Torr O2. The numerical values above each
plateau represent the estimated mean cellular PO2. C. Michaelis-Menten plot. The
calculated KmO2 was 22 (SD 6) Torr. The calculated Vmax was 4.9 (SD 0.4) nmol/min·106
cells.
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Figure 4.

Effect of O2 tension on iNOS protein concentration. Representative western blot of SDSPAGE gel for inducible nitric oxide synthase (iNOS) in LPS and IFNγ stimulated RAW
264.7 cells exposed to 6, 36, or 157 Torr O2 for 40 minutes. iNOS signal was normalized
to RAF-1, a constitutively expressed protein. The bar graph presents the mean (SD) of
the iNOS to RAF-1 ratio at each PO2 (n ≥ 4). (-) Unstimulated RAW 264.7 cells exposed
to 36 Torr O2 for 40 minutes.
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Figure 5.

Effect of O2 tension on iNOS dimerization. A. Western blot of low temperature SDSPAGE gel for inducible nitric oxide synthase (iNOS) in LPS and IFNγ stimulated RAW
264.7 cells exposed to 6, 36, or 157 Torr O2 for 40 minutes. M = Hi-Mark pre-stained
molecular weight marker (Invitrogen, Carlsbad CA). RA = RAW 264.7 cells grown in
room air. CL = RAW 264.7 cells cultured in room air and treated with 10 µM
clotrimazole, an inhibitor of iNOS dimerization (232), for 30 minutes prior to and during
stimulation with LPS and IFNγ for 8 hours. Stim = RAW 264.7 cells were unstimulated
(-) or stimulated (+) for 18 hours with LPS and IFNγ. Flow = RAW 264.7 cells grown in
culture dishes (-) or with forced convection (+). B. Bars represent the mean (SD) of the
260 kD to 130 kD ratio (n = 3). * p = 0.003 compared to 36 Torr. C. Bars represent the
mean (SD) of the 500 kD to 130 kD ratio (n = 3). * p = 0.008 compared to 36 Torr.
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Figure 6.

Effect of NO and O2 tension on cellular NO consumption. A. Representative tracing of
1400W inhibition of NO produced by LPS and IFNγ stimulated RAW 264.7 cells (n =
12). Cells were switched from JBMEM to 100 µM 1400W in JBMEM lacking Larginine (labeled 1400W). Effluent PNO was measured approximately every 10 minutes
for 2 minutes (labeled NO). B. Representative tracing showing effluent PNO measured
during sequential exposure of 1400W-inhibited cells to 40, 79, 160, 319, and 500 ppm
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input PNO as labeled, and 0 ppm NO (labeled Cell NO; n = 8). O2 tension was 6 Torr. C.
Cellular NO consumption by LPS and IFNγ stimulated RAW 264.7 cells treated with the
iNOS inhibitor 1400W was measured as a function of O2 and NO tension. Each bar
represents the mean (SD) of the ratio of the effluent PNO with cells to the effluent PNO
without cells for five input PNO and three PO2 (n ≥ 2). Reference line = 1. Ratios < 1 =
net NO consumption. Ratios > 1 = net NO production.
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Figure S1.
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Dependence of cellular NO consumption on NO tension. Plots of QαNO(PNOi-PNOe) versus
PNO for individual columns at 6, 36, or 83 Torr O2. The lines represent the linear
regression.
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Figure S2.
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Dependence of cellular NO consumption on PO2. Plot of b1/PO2 versus PO2 (n ≥ 2),
where b1 = the best fit slope of the QαNO(PNOi-PNOe) versus PNO data presented in Figure
S1.
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Table 1. NO Consumption in DMEM.
Component
DMEM (Gibco)
GibcoTM essential
amino acid mixture (1X)
NaHCO3 (3700 mg/L)
Glucose (4500 mg/L)
Glucose (1000 mg/L)
NaCl (6400 mg/L)
deionized H2O

% Consumption
99.9
72
48
36
15
7
0

Using the forced convection cell culture system and NO electrode, effluent NO was
measured in DMEM and select components after a 29 second exposure to 80 ppm input
NO in the absence of cells and O2. The signal generated by the exposure of deionized
H2O at 0 Torr O2 to 80 ppm NO was designated 0% consumption.
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Table 2. Cell survival in DMEM and JBMEM.

Media

2

Time (hours)
6

DMEM (U)
DMEM (S)
JBMEM (U)
JBMEM (S)

95.1 (2.7)
94.8 (0.9)
91.2 (4.7)
94.0 (0.4)

97.4 (0.9)
94.5 (1.3)
90.9 (2.3)
94.4 (0.5)

18
90.2 (3.9)
ND
88.0 (5.1)
ND

RAW 264.7 cells were cultured for 2, 6, or 18 hours in DMEM or JBMEM with (S) or
without (U) stimulation (1 µg/ml LPS and 100 U/ml IFNγ initiated 18 hours prior to
seeding; n = 3). Percent survival was measured via Trypan blue staining. Data are
presented as mean (SD). ND = not determined.
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ABSTRACT
Stimulated macrophages produce nitric oxide (NO) via inducible nitric oxide
synthase (iNOS) using molecular O2, L-arginine, and NADPH. Exposure of
macrophages to hypoxia decreases NO production within seconds due to limitation of the
reactant(s). Conflicting data exist regarding the effect of pO2 on NADPH production via
the oxidative pentose phosphate cycle (OPPC). Therefore, the present studies were
developed to determine whether NADPH could be limiting for NO production under
hypoxia. Production of NO metabolites (NOx) and OPPC activity by RAW 264.7 cells
was significantly increased by stimulation with lipopolysaccharide (LPS) and interferon γ
(IFNγ) at pO2 ranging from 0.07% to 50%. OPPC activity exhibited a linear dependence
on NOx production at pO2 > 0.13%. Increased OPPC activity by stimulated RAW 264.7
cells was significantly reduced by 1400W, an iNOS inhibitor. OPPC activity was
significantly increased by concomitant treatment of stimulated RAW 264.7 cells with
chemical oxidants, hydroxyethyldisulfide or pimonidazole, at 0.07% and 50% O2,
without decreasing NOx production. These results are the first to demonstrate the
relationship between NO production and OPPC activity over a wide range of pO2, and to
rule out limitations in OPPC activity as a mechanism by which NO production is
decreased under hypoxia.
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INTRODUCTION
Nitric oxide (NO) production is a key component of the macrophage response
during inflammation (33, 172). Macrophages stimulated by pathogen associated
molecular patterns (PAMPs) produce NO from molecular O2, L-arginine, and NADPH
via inducible nitric oxide synthase (iNOS) (245). NO production clearly depends on the
partial pressure of O2 (pO2) (179, 202, 218), and the estimated cellular KmO2 (14 Torr
(202) to 77 ± 1.4 Torr (179)) is within the physiological range (5 to 71 Torr (23, 37, 42,
124, 129, 263, 282)). Systemic and/or tissue hypoxia develops during several
inflammatory diseases (42, 75, 122), extending the pO2 range for tissue macrophages to
even lower levels, and potentially limiting NO production in vivo. Acute exposures to
hypoxia have been shown to rapidly (within seconds) and reversibly decrease NO
production by PAMPs stimulated macrophages without decreasing iNOS protein or
assembly (218), providing evidence for the dynamic regulation of NO production by
substrate limitation. While molecular O2 is clearly limiting, an effect of hypoxia on the
electron donor NADPH represents a second potential mechanism that has not been
investigated in macrophages.
NADPH is constitutively produced by NADP+ dependent malic enzyme and
isocitrate dehydrogenase. When NADPH oxidation exceeds the capacity of these
enzymes to reduce the substrate, however, the increase in [NADP+] activates glucose-6phosphate dehydrogenase (G6PD), the initial and rate limiting enzyme of the oxidative
pentose phosphate cycle (OPPC) (68). An association between NADPH production by
G6PD and the production of NO has previously been demonstrated in endothelial cells
(156-158), an insulin-producing pancreatic beta cell line (RINm5F) (98), and
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macrophages (57, 112, 180, 258). In macrophages, stimulation with PAMPs was found
to elicit a parallel increase in OPPC activity (153, 177, 191) and NO production (57), by
increasing G6PD activity and metabolic flux through the OPPC, rather than via the malic
enzyme (58). Moreover, pharmacologic inhibition of OPPC activity or G6PD deficiency
was shown to significantly impair NO production by stimulated macrophages (112, 180,
258).
Reduction of NADP+ via the OPPC does not require molecular O2. Classical
studies have measured increased [NADPH] in response to short term hypoxia due to the
absence of metabolically-generated oxidizing agents (99, 127, 227, 259). More recently,
however, [NADPH] was found to be significantly decreased in denuded bovine coronary
arteries following brief exposure to hypoxia (~ 8 to 10 Torr, 20 minutes (100)). This
effect was attributed to increased glycolytic flux, resulting in the redirection of substrate
(glucose-6-phosphate) away from the OPPC. However, OPPC activity was not directly
measured in these experiments. These results suggest NADPH availability may be
limited during acute hypoxia in some tissues and/or cell types.
NADPH production via the OPPC maintains the cellular redox equilibrium (16).
Therefore, to investigate whether OPPC activity was limited during acute hypoxia, the
cells were simultaneously exposed to hydroxyethyldisulfide (HEDS) or pimonidazole
(PIMO) to pharmacologically induce oxidative stress by two distinct mechanisms. HEDS
is a low molecular weight, cell permeable disulfide that is reduced by exchange reactions
with glutathione and other cellular thiols. These oxidized cellular thiols are subsequently
reduced by NADPH-dependent glutathione and thioredoxin reductases (18, 26, 27).
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PIMO is reduced by cytochrome P450 enzymes, which also utilize NADPH to provide
reducing equivalents (264).
The primary goal of this study was to investigate the relationship between pO2
(0.07% to 50%), NO production, and OPPC activity in PAMPs stimulated and
unstimulated macrophages (Figure 1). We chose to study RAW 264.7 cells due to the
extensive literature on the pO2 dependence of NO production in these cells (179, 202,
218), and due to their abundant and persistent NO production (61). We hypothesized that
4 hours of hypoxia would decrease NO production and OPPC activity without affecting
iNOS concentration or iNOS dimerization. Second, we hypothesized that pO2 would not
affect the response of OPPC activity to chemically-induced oxidative stress via HEDS or
PIMO. Our results suggest that pO2, and not NADPH availability, affects NO production
by PAMPs stimulated macrophages during acute hypoxia.
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METHODS
Cell Culture
RAW 264.7 cells (American Type Culture Collection, Manassas, VA) were
maintained at 37°C 5% CO2 in DMEM (Invitrogen, Carlsbad, CA) supplemented with
10% FBS (HyClone, Logan, Utah) and 1% antibiotic/antimycotic (penicillin,
streptamycin, amphotericin B; Invitrogen) for up to 10 passages. For experiments, 106
cells were plated on 20 mL glass vials (inner diameter ~ 24 mm), or 1.5 x 106 cells were
spot platted on 50 mm glass dishes (143). Glass dishes and vials were cleaned and fired
at 420°C, then treated with 75 mM sodium carbonate (Fisher, Fair Lawn, NJ) and 15%
FBS for 1 hour at 37°C, treated with 0.2% gelatin (BioRad, Richmond, CA) for 20
minutes, and dried under UV light prior to plating the cells. Cells were then cultured
overnight with 3 mL of MEM (Invitrogen, 11095) supplemented with penicillin,
streptomycin, 15% FBS, non-essential amino acids, and 1 mM pyruvate. Stimulation of
RAW 264.7 cells was performed by treating cells overnight (at least 18 hours) with 1 µg/
mL LPS (E. coli O111:B4; Sigma) and 100 U/mL CHO-derived recombinant mouse
IFNγ (Cell Sciences, Canton, MA). Immediately prior to experiments, the media was
replaced with 1 mL of low glucose (2 mM) MEM buffered with 25 mM HEPES (i.e.
instead of sodium bicarbonate to prevent saturation of the filter paper with unlabeled CO2
during the measurement) and containing 5% FBS, non-essential amino acids, 1%
penicillin and streptomycin, and 2 mM glutamine. HEPES-buffered media pH was not
affected by pO2 or any of the other treatment conditions (data not shown). Where
indicated, NOx production was inhibited by treating cells with 100 µM N-[[3(aminomethyl)phenyl]methyl]-ethanimidamide, dihydrochloride (1400W; Cayman
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Chemical, Ann Arbor, MI) in the absence of L-arginine for one and one half hours
immediately prior to switching to low glucose media. To chemically induce oxidative
stress, 2 mM hydroxyethyldisulfide (HEDS) or 2 mM pimonidazole (PIMO) were added
to the low glucose media.

pO2 Control with Thin Film Cell Culture
RAW 264.7 cells were cultured at 0.07%, 0.13%, 0.24%, 0.61%, 2%, 10%, or
50% O2 for 4 hours at 37°C in vials or dishes contained in leak proof aluminum
chambers, which enabled precise control of headspace pO2 as previously described (142144, 259). Briefly, glass vials were capped with a rubber stopper containing a center well
(Kimble Chase, Vineland, NJ) with a 1 × 0.5 cm Whatman GF/B glass-fiber filter soaked
with 100 µL 5% KOH (259). A 25G 5/8 inch needle was inserted into the stopper to
enable slow gas exchange during the evacuations and pressurizations for oxygen control,
while limiting gas exchange under the constant pressure conditions during the subsequent
incubation (259). Vials or dishes were placed in aluminum chambers and subjected to a
series of gas exchanges with N2 or O2 to produce the desired headspace pO2. Chambers
were warmed to 37°C and shaken continuously to ensure adequate gas exchange between
the headspace and the media throughout the experiment (4 hours). The pO2 in the
chambers was measured at the end of the incubation period using a polarographic oxygen
electrode. However, the pO2 in the headspace of each vial was not directly accessible.
Additionally, the depth of the medium layer in the vials did not conform to the “thinlayer” model that was originally developed in 50 mm glass dishes (143). Thus, in
separate experiments, we added 100 µM EF5 to both dishes and vials, and assayed for
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EF5 adducts using flow cytometry as previously described (141, 142) in order to directly
assess cellular pO2. Note that in the experiments presented, pO2 is defined as the % of
oxygen in 1 atmosphere of dry gas at 37°C (i.e. 100% = 760 mm of Hg).

NOx Measurement
Nitrite, nitrate, and nitrosothiols (NOx) were measured in media or cell lysates by
injecting 20 µL into a reaction chamber containing a VCl3/HCl mixture (0.4 g VCl3 in 50
mL 1 N HCl) heated to 90°C. The resulting NO was continuously flushed with helium
into a Sievers Nitric Oxide Analyzer 280i (GE Analytical Instruments, Boulder, CO) for
reaction with ozone and measurement via chemiluminescence. Quantification was
performed by comparison to standards prepared with NaNO2.

Electrophoresis and Immunoblotting
Cell lysates were prepared by washing cell monolayers with ice cold cell rinse
(6.8 g/L NaCl, 400 mg/L KCl, 122 mg/L NaH2PO4 anhydrous, 1 g/L glucose, 25 mM
HEPES, pH 7.2), and then scraping cells into 0.4 mL ice cold protease-inhibitor
containing hypotonic lysis buffer (1:1000 Protease Inhibitor Cocktail P8340 (SigmaAldrich, St. Louis, MO), 10 µM phenylmethylsulfonyl fluoride (Sigma-Aldrich) in
dH2O). Lysates were subjected to 3 freeze/thaw cycles (-70°C). Cell lysate protein
concentration was measured using the Biorad DC protein assay (Hercules, CA). Proteins
(5 µg) were separated on a 7.5% Tris-HCl gel using SDS PAGE or low temperature SDS
PAGE (LT SDS PAGE) as previously described (218), transferred to polyvinylidene
fluoride (ImmobilonTM-FL 0.45 µm; Millipore, Bedford, MA), and immunoblotted for
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iNOS (1:2000; NOS2 M19 sc650, Santa Cruz Biotechnology, Inc., Santa Cruz, CA). β
actin (1:20,000; Monoclonal anti-β actin Clone AC-15 A5441, Sigma-Aldrich) was used
as the loading control. Primary antibodies were immunocomplexed with IRDyeTM 800
goat anti-rabbit or goat anti-mouse (1:10,000; Rockland, Gilbertsville, PA). Proteins
were detected, documented, and analyzed using an Odyssey Imaging System and
software (LiCor Biosciences, Lincoln, NE).

OPPC and TCA Activity
RAW 264.7 cells were cultured in the presence of 2 mM glucose labeled in either
the 1-14C or 6-14C position at a specific activity of 200 µCi/mmol glucose in 1 ml of
bicarbonate-free MEM. At the completion of each experiment, the vials were removed
from the aluminum chambers, the needle was removed from the rubber stopper, and
cellular metabolism was stopped by injection of 100 µL 6 N acetic acid into the media;
the acidification step also releases CO2 from the medium into the gas phase.

14

CO2 was

collected on a 5% KOH saturated filter overnight at room temperature. The filter was
removed and the 14CO2 was counted with a Packard liquid scintillation counter. TCA
activity leads to release of 14CO2 from either the 1-14C or 6-14C position of glucose, while
OPPC activity causes release of 14CO2 only from the 1-14C position. Thus, OPPC activity
was calculated using parallel vials and subtracting 14CO2 produced in the presence of 614

C glucose from the 14CO2 produced in the presence of 1-14C glucose.
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Statistics
The apparent Km and Vmax values were calculated by SigmaPlot Enzyme Kinetics
Module 1.1 using a Michaelis-Menten non-linear analysis. Comparison of means were
tested by ANOVA for the effect of pO2 on measured values, and by two way ANOVA for
the effect of pO2 and treatment on measured values. Data presented are mean ± SD.
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RESULTS
Control of Cellular pO2
Cellular pO2 was regulated using a modified version of the Thin Film Culture
Method developed in our laboratory (143). To ensure the modified method (i.e. glass
vials with rubber stopper and needle) provided the same pO2 at the cellular level, we
compared the cellular pO2 in glass dishes with the cellular pO2 in glass vials via the
measurement of EF5 protein adducts (Figure 2). The formation of EF5-protein adducts
increases as the pO2 decreases in a quantitative manner, thus permitting an accurate
measurement of cellular pO2 because the pO2 is constant between the gas and liquid
phases (143). The pO2 dependence of EF5 binding for RAW 264.7 cells incubated on
glass dishes was similar to results from other cultured cell lines (141). Importantly, the
EF5 binding for cells in glass vials closely paralleled EF5 binding for cells on glass
dishes (Figure 2).

pO2 dependence of NOx production
NOx, iNOS protein levels, and iNOS dimerization were measured using the thin
film cell culture method and low glucose media required for the OPPC measurements.
The results obtained in low glucose media were similar to previous cell culture systems
(Figure 3 and references (202, 218)). Cumulative NOx released into the media by LPS
and IFNγ-stimulated RAW 264.7 cells fit a Michaelis-Menten kinetic model with a KmO2
of 0.66 ± 0.12 % (5 ± 1 Torr) and a Vmax of 25.2 ± 1.0 nmol/106 cells (R2 = 0.91, Figure
3A). NOx measured in cell lysates from LPS and IFNγ-stimulated RAW 264.7 cells
exposed to 50% O2 for 4 hours was 3.5 ± 1.1 nmol/106 cells, 13% of NOx detected in the
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media. In the absence of LPS and IFNγ stimulation, RAW 264.7 cells did not produce
detectable NOx (data not shown). pO2 did not alter iNOS protein concentration (Figure
3B) or iNOS dimerization (Figure 3C). Stimulation of RAW 264.7 cells with LPS and
IFNγ decreased total protein isolated from the vials by 30%, consistent with previous
reports (200, 218). pO2 alone did not affect cell adhesion as visualized by light
microscopy, or the amount of total protein isolated from the vials (data not shown).

pO2 dependence of OPPC Activity
Unstimulated RAW 264.7 OPPC activity exhibited a biphasic response to pO2
(Figure 4A), with a decrease between 0.07% and 2% O2 and a 2.5 fold increase between
10% and 50% O2. Stimulation of RAW 264.7 cells with LPS and IFNγ for 18 hours
significantly increased OPPC activity at all pO2 (p < 0.001). OPPC activity correlated
directly with NOx production for pO2 greater than 0.13% O2 in LPS and IFNγ stimulated
cells (Figure 4B). Treatment of LPS and IFNγ stimulated RAW 264.7 cells with 1400W,
an iNOS inhibitor, completely inhibited NOx production (Table 1), and significantly
decreased OPPC activity to levels observed without LPS and IFNγ treatment (p < 0.001;
Figure 4A, Table 1). 1400W also decreased OPPC activity in unstimulated RAW 264.7
cells (Table 1) and unstimulated RAW 264.7 cells treated with PIMO (data not shown) at
50% O2, but not 2% and 0.07% O2, suggesting possible nonspecific effects of the
treatment at 50% O2. Treatment of RAW 264.7 cells with LPS and IFNγ decreased TCA
activity (Table 1), consistent with NOx-mediated respiratory inhibition (reviewed by
(40)). Treatment with 1400W, however, did not reverse the observed affect on TCA
activity at any pO2 (Table 1).
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OPPC Challenge with HEDS and PIMO
To further increase oxidative challenge, RAW 264.7 cells were treated with
HEDS or PIMO, two chemical oxidants, which operate by distinct mechanisms. HEDS
or PIMO both increased OPPC activity significantly in RAW 264.7 cells at either 0.07%
O2 and 50% O2 (p < 0.001, Figure 5). Stimulation of RAW 264.7 cells with LPS and
IFNγ did not alter the magnitude of the increase in OPPC activity induced by HEDS or
PIMO treatment. NOx production was measured during OPPC challenge to determine
whether NO production was maintained despite chemical oxidant stress (i.e. to assess
whether OPPC capacity was able to accommodate both processes). NOx production by
LPS and IFNγ stimulated RAW 264.7 cells was not affected by HEDS treatment at
0.07% O2 or 50% O2 (Figure 6). PIMO, a nitroimidazole, was detected by the nitric
oxide analyzer (2 mM PIMO in media generated the equivalent signal of 3.6 µM
NaNO2). Even after correcting for this signal, however, NOx measurements were
significantly increased in PIMO treated LPS and IFNγ stimulated RAW 264.7 cells at
0.07% O2 (p < 0.05) and 50% O2 (p < 0.001), suggesting PIMO might be metabolized to
nitrite, nitrate, or nitrosothiols (178).
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DISCUSSION
Increased NOx production and increased OPPC activity were observed over a
wide range of pO2 (0.07% to 50% O2) in LPS and IFNγ stimulated RAW 264.7 cells,
consistent with previous reports of a relationship between NO production and NADPH
oxidation in atmospheric O2 (57, 98, 112, 156-158, 180, 258). Moreover, inhibition of
NO production significantly decreased OPPC activity at all pO2 investigated, suggesting
that the majority of the increased OPPC activity observed in stimulated RAW 264.7 cells
was directly related to NO and/or reactive nitrogen species production. Hypoxia did not
inhibit the ability of the OPPC to respond to chemically mediated oxidative stress
induced by HEDS or PIMO, and HEDS did not inhibit NOx production in stimulated
cells. These results demonstrate that OPPC activity is not limiting for NO production by
stimulated RAW 264.7 cells irrespective of pO2.
The pO2 dependence of NOx production was well fit by a Michaelis-Menten
model, and the measured KmO2 (0.66% or 5 Torr) was within the range reported
previously (5 Torr to 96 Torr) (1, 67, 179, 202, 214, 218). Despite substantial differences
in experimental methodology, these data are consistent with our previous results using
forced convection cell culture (22 Torr) (218), and our previous data from cell
monolayers grown in dishes for 18 hours, after correction for iNOS activity and media
depth (14 Torr) (202). The data are also consistent with measurements made by
Rengasamy and Johns using RAW 264.7 cell lysates and a steady state system (5 Torr)
(214). In contrast, rapid equilibrium studies with recombinant iNOS reported apparent
KmO2 values of 93 Torr (1) and 96 Torr (67). At present, the reasons underlying the > 10
fold higher apparent KmO2 measured with recombinant iNOS are unclear. Regardless, the
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range of pO2 found in vivo (5 to 71 Torr (23, 37, 42, 75, 122, 124, 129, 263, 282)) has the
potential to significantly and rapidly affect NO production, as suggested previously (1,
67, 179, 202, 214, 218).
The pO2 dependence of NOx production was not due to changes in iNOS protein
levels or iNOS dimerization, consistent with our previous studies of short-term hypoxia
(40 minutes) (218). Multiple studies have documented the affects of long-term (18 to 24
hours) hypoxia on iNOS upregulation via HIF 1α (126, 181, 182). Increased expression
of iNOS protein due to hypoxia, however, requires incubations greater than or equal to 6
hours (4). The half-life of iNOS in atmospheric O2 is approximately 1.6 hours (145), but
the effect of hypoxia on stability of the protein has not been investigated. Based on the
present study, we conclude that short-term hypoxia (i.e. < 4 hours) has negligible effects
on the balance between transcription, translation, assembly, and degradation of iNOS.
Several previous studies have investigated the effects of short term hypoxia on
NADPH and/or OPPC activity (99, 100, 127, 227, 259), but we have found no prior
studies that examined the pO2 dependence of OPPC activity in macrophages.
Interestingly, OPPC activity in unstimulated RAW 264.7 cells exhibited a biphasic pO2
dependence in contrast to our previous work in HT1080 (human fibrosarcoma) and A549
(human lung carcinoma) cells (259). One potential source of NADP+ under hypoxia is
the mitochondrial transhydrogenase. The decrease in mitochondrial respiration observed
under severe hypoxia results in elevated glycolytic flux, to maintain [ATP]. Hypoxic
glycolysis produces lactate and NAD+. Mitochondrial transhydrogenase couples
reduction of NAD+ to oxidation of NADPH (128). This reaction has been shown to
increase under anaerobic conditions (241). We propose that the NADP+ produced by the
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mitochondrial transhydrogenase catalyzed reaction resulted in the stimulation of OPPC
activity that we observed under hypoxia. While we are examining this hypothesis more
thoroughly, it is important to note that the increase of OPPC activity between 2% and
0.07% for unstimulated RAW 264.7 cells under hypoxia, though statistically significant,
is relatively small compared to the increase observed between 10% and 50% O2, or
compared to the increase observed in LPS and IFNγ stimulated cells.
Stimulation of RAW 264.7 cells with LPS and IFNγ significantly increased OPPC
activity at all pO2, thus extending previous reports for PAMPs stimulated macrophages in
atmospheric O2 (58, 153, 191, 192). These results are consistent with our results
previously obtained in tumor cells (259), and conform with the classical view of
decreased metabolic flux through the OPPC under hypoxia (99, 127, 227), whereby
removal of O2 leads to a reducing environment. For example, Scholz et al. measured an
increase in NADPH fluorescence in rat liver within seconds of exposure to near anoxic
pO2, and measured a new steady state within minutes (227). Treatment with the iNOS
inhibitor, 1400W, significantly reversed the affect of LPS and IFNγ stimulation at all
pO2, suggesting the increase in OPPC activity was to accommodate NO production
and/or the neutralization of reactive nitrogen mediated stress. Although NADPH may
also be consumed by NADPH oxidase (149), or even by iNOS to produce superoxide
(247), superoxide release by LPS and IFNγ stimulated RAW 264.7 cells is reported to
only occur within the first hour after stimulation (203), and to be only 6 % of NO
production (11, 190).
OPPC activity correlated linearly with NOx production above 0.13% O2, with a
slope of approximately 2, suggesting that for each molecule of NOx measured, 4
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molecules of NADPH were consumed. NO production is reported to require 1.5
molecules of NADPH per NO molecule (reviewed by (247)), leaving a theoretical excess
of 2.5 NADPH molecules. One possibility for this excess is that NADPH is required to
maintain cellular redox equilibrium in the presence of reactive oxygen and nitrogen
mediated stress (reviewed by (16, 73)). Another possibility is a limitation associated with
our measurements: NOx does not account for all NO metabolites, or for the NO released
into the gas phase of the vial. Since the thin film culture system is designed to keep the
gas phase in equilibrium with the liquid phase, it is not technically possible to confine
NO to the media. Because NO production was not measured via radiolabeled L-arginine,
it is impossible to calculate the amount of NO released into the gas phase. Therefore, the
absolute relationship between NO, NOx production, and NADPH consumption remains
to be addressed by additional studies.
Because OPPC activity decreased with pO2, we investigated whether OPPC
activity was limited by hypoxia. HEDS and PIMO are chemical oxidants that induce
oxidative stress by mechanisms that are not dependent on pO2 (18, 26, 27, 264). Thus,
these compounds were used to challenge the OPPC in RAW 264.7 cells under hypoxia.
Treatment with HEDS or PIMO significantly increased OPPC activity under all
conditions tested including hypoxia. To further investigate the relationship between
OPPC activity and NOx production, we measured NOx production in LPS and IFNγ
stimulated RAW 264.7 cells exposed to HEDS, and found that NOx production was
maintained despite this chemical challenge to the OPPC. Therefore, we conclude that
OPPC activity is not limiting for NO production in stimulated RAW 264.7 cells.
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In summary, OPPC activity was increased following stimulation with LPS and
IFNγ at all pO2 investigated in RAW 264.7 macrophages, a response which appears to be
a direct consequence of NO production. OPPC activity under conditions of chemically
mediated oxidative stress (i.e. HEDS or PIMO treatment) was not limited by hypoxia, nor
was it limiting for NO production under any of the conditions investigated. Finally, we
conclude that O2 substrate limitation is the primary mechanism responsible for decreased
NO production by LPS and IFNγ stimulated macrophages exposed to acute hypoxia.
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Figure 1.

Schematic of the relationship investigated between NOx production and OPPC activity.
The production of 1 molecule of NO consumes 1.5 NADPH molecules (247). The NO
metabolites (NOx) measured in this study include nitrite, nitrate, and nitrosothiols in the
extracellular media (see Methods). The OPPC produces 2 molecules of NADPH per
molecule of CO2 released. OPPC activity was measured as the production of 14CO2 from
14

C-labeled glucose minus the 14CO2 produced by the TCA cycle (see Methods).
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Figure 2.

EF5 binding in Glass Dishes versus Vials. RAW 264.7 cells were cultured for 3 hours in
the presence of 100 µM EF5 at 0.03%, 0.14%, 0.21%, 0.59%, 1.04%, 1.91%, or 11.7%
O2. RAW 264.7 cells were labeled with an EF5-specific Cy5 antibody and EF5 binding
was measured by flow cytometry of a single cell suspension. Results across experiments
were normalized to a positive control. Note that in the experiments presented, pO2 is
defined as the % of oxygen in 1 atmosphere of dry gas at 37°C (i.e. 100% = 760 mm of
Hg).
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Figure 3.

NOx production, iNOS protein concentration, and iNOS dimerization in LPS and IFNγ
stimulated RAW 264.7 cells cultured with Thin Film Cell Culture. LPS and IFNγ
stimulated RAW 264.7 cells were exposed to 0.07%, 0.13%, 0.24%, 0.61%, 2%, 10%, or
50% O2 (balance N2) for 4 hours using Thin Film Cell Culture. A. Media NOx were
converted to NO via reaction with vanadium chloride and measured with a Sievers Nitric
Oxide Analyzer (see Methods). Data presented are mean ± SD. (n ≥ 3). B, C.
Representative western blots of an SDS-PAGE gel (B) and a low temperature SDSPAGE gel (C) for iNOS and β actin. (n ≥ 3). (R) RAW 264.7 cells grown in atmospheric
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O2. (+) RAW 264.7 cells treated with LPS and IFNγ for at least 18 hours prior to
exposure to the designated pO2. (-) RAW 264.7 cells not treated with LPS and IFNγ.
(M) BioRad Kaleidoscope Prestained Standards (BioRad, Hercules CA).
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Figure 4.

Correlation between OPPC activity and NOx production. A. RAW 264.7 cells (closed
circles), LPS and IFNγ stimulated RAW 264.7 cells (open circles), or LPS and IFNγ
stimulated RAW 264.7 cells pretreated with the iNOS inhibitor, 1400W at 100 µM (open
triangles) were incubated with 1-14C glucose or 6-14C glucose in parallel experiments at
0.07%, 0.13%, 0.24%, 0.61%, 2%, 10%, or 50% O2 (balance N2). Cumulative OPPC
activity was calculated by subtracting 14CO2 produced in the presence of 6-14C glucose
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(TCA Activity) from 14CO2 produced in the presence of 1-14C glucose (OPPC Activity +
TCA Activity). OPPC activity by LPS and IFNγ stimulated RAW 264.7 cells was
significantly different from RAW 264.7 cells and LPS and IFNγ stimulated RAW 264.7
cells + 1400W at all pO2 (p < 0.001). At this concentration (100 µM), 1400W did not
completely inhibit the enhanced OPPC activity resulting from LPS and IFNγ stimulation.
Data presented are mean ± SD. (n ≥ 4) B. Linear regression of OPPC activity and NOx
production (data shown in Figure 2). y = [b1]x + [b0]
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Figure 5.

OPPC Challenge with HEDS and PIMO. OPPC activity of RAW 264.7 cells and LPS
and IFNγ stimulated RAW 264.7 cells was measured during treatment with one of two
chemical oxidants, HEDS (2 mM) or PIMO (2 mM), at 0.07% and 50% O2 for 4 hours.
(*) Significant effect of HEDS or PIMO treatment on OPPC activity versus no treatment
(p < 0.001). Data presented are mean ± SD. (n = 4)
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Figure 6.

NOx production during OPPC challenge with HEDS and PIMO. RAW 264.7 cells and
LPS and IFNγ stimulated RAW 264.7 cells were treated with 2 mM HEDS or 2 mM
PIMO during a 4 hour exposure to 0.07% or 50% O2. Media NOx were converted to NO
via reaction with vanadium chloride and measured with a Sievers Nitric Oxide Analyzer.
PIMO data were corrected for the signal of PIMO in media (3.64 nmol). A statistically
significant effect of HEDS or PIMO on NOx versus no treatment was calculated where
indicated (* p < 0.05, ** p < 0.001). Data presented are mean ± SD. (n ≥ 3).
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Table 1. Effect of 1400W on RAW 264.7 NOx Production, OPPC activity, and TCA
activity.

NOx
6

% pO2

0.07

0.07

2

2

50

50

1400W

-

+

-

+

-

+

1.5 ± 2.1

ND

0.1 ± 1.1

ND

0.2 ± 0.3

ND

NS

nmol/10 cells

S

4.9 ± 3.0 *

0.0 ± 0.5 †

15.5 ± 2.8 *

ND

26.4 ± 1.5 *

0.3 ± 1.3 †

OPPC

NS

14.7 ± 3.8 ‡

10.7 ± 1.7

7.4 ± 0.9

5.0 ± 1.9

25.1 ± 7.9 ‡

9.7 ± 1.0 §

nmol CO2/106 cells

S

25.0 ± 2.2 a

13.1 ± 0.4 b

59.0 ± 4.8 a

18.8 ± 1.9 a,b

71.8 ± 7.3 a

27.9 ± 5.3 a,b

TCA

NS

0.3 ± 0.1

0.2 ± 0.02

1.7 ± 0.4

4.9 ± 0.4 c

4.1 ± 2.9

5.78 ± 2.9

nmol CO2/106 cells

S

0.4 ± 0.1

0.3 ± 0.01

0.6 ± 0.04

0.3 ± 0.04 d

0.6 ± 0.04 d

0.3 ± 0.1 d

RAW 264.7 cells were stimulated (S), or not (NS), with 1 µg/mL LPS and 100 U/mL
IFNγ prior to exposure to 4 hours of 0.07%, 2%, or 10% O2 with Thin Film Cell Culture.
RAW 264.7 cells were treated with 100 µM 1400W (+), or not (-), for 1 ½ hours prior to
Thin Film Cell Culture. (ND) = not determined. (*) Effect of LPS and IFNγ treatment
on media NOx (0.07% p < 0.05; 2% and 50% p < 0.001). (†) Effect of 1400W treatment
on media NOx (0.07% p < 0.01, 50% p < 0.001). (‡) Effect of pO2 on RAW 264.7 OPPC
activity (0.07% and 50% > 2%, p < 0.05). (§) Effect of 1400W treatment on RAW 264.7
cells OPPC activity (p < 0.001). (a) Effect of LPS and IFNγ treatment on OPPC activity
(p < 0.001). (b) Effect of 1400W treatment on OPPC activity by LPS and IFNγ
stimulated RAW 264.7 cells (p < 0.001). (c) Effect of 1400W on TCA activity (p < 0.05).
(d) Effect of LPS and IFNγ treatment on TCA activity (Without 1400W p < 0.01, With
1400W p < 0.001). Data presented are mean ± SD. (NOx n ≥ 3, OPPC n ≥ 4, TCA n ≥
2).
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CHAPTER 3.
EFFECT OF CHANGING EXTRACELLULAR L-ARGININE
CONCENTRATION ON MACROPHAGE NO PRODUCTION

Mary A. Robinson

Unpublished Data
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INTRODUCTION
L-arginine is a substrate for NO production by iNOS; the nitrogen in NO is
derived from either of the guanidino nitrogens of L-arginine (120, 206). Pharmacological
inhibition of iNOS can be obtained in vivo and in vitro with 1400W, an L-arginine analog
that contains an amidine and an amine substituted for the guanidino groups (82). Once
1400W binds to the L-arginine binding site, it is slowly reversible with a dissociation
constant (Kd) of 7 nM (82). L-arginine competes directly with 1400W binding to iNOS
with a binding constant (Ks) of 2.2 µM (82), similar to the iNOS apparent Km for
arginine (2.8 µM (245)). The concentration of L-arginine in the cell culture media used
for our studies was 300 (JBMEM) and 700 µM (MEM). Therefore, in the studies
describe in Chapters 1 and 2, incubations with 1400W were performed in media prepared
without L-arginine to optimize inhibition kinetics. Inhibition of NO production by
exposure to 1400W (100 µM) in media prepared without L-arginine was measured
directly in the forced convection cell culture system (Chapter 1, Figure 6B). To
differentiate the effect of 1400W on NO production from the effect of changing the
extracellular L-arginine concentration, NO production was also measured in real time
during exposure to L-arginine deficient media. This experiment revealed some
interesting kinetics of L-arginine removal and replacement.
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METHODS
RAW 264.7 cells (American Type Culture Collection, Manassas, VA) were
cultured using the forced convection cell culture system described in Chapter 1 Methods
(22). Cells were stimulated overnight (18 to 24 hours) with 1 µg/ml LPS (E. coli
O111:B4; Sigma) and 100 U/ml CHO-derived recombinant mouse IFNγ (Cell Sciences,
Canton, MA). Then, cells were perfused with a minimal essential media (JBMEM: 140
mM NaCl, 1.4 mM CaCl2, 5.3 mM KCl, 4.4 mM Dextrose, 25 mM HEPES, 0.3 mM Larginine, and 0.1% heat-inactivated FBS (LONZA)) and NO production was measured
with an NO electrode as described in Chapter 1 Methods. Once baseline NO production
was established, the cells were perfused with L-arginine deficient media (JBMEM
without L-arginine) for 1 hour. The cells were returned to L-arginine replete media, and
the effect on NO production was measured. The pO2 for these experiments was 36 Torr
O2.
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RESULTS AND DISCUSSION
Perfusing the cells with L-arginine deficient media decreased NO production, but
did not eliminate it (Figure 1). NO production achieved a new steady state within 15
minutes at approximately 20% of the initial NO production level. One hour later, when
the cells were returned to L-arginine replete media, NO production immediately (within
seconds) recovered to the initial measured level (Figure 1).
These results suggest that the majority of the L-arginine utilized for NO
production by LPS and IFNγ stimulated RAW 264.7 cells was transported into the cell,
and are consistent with previous observations of extracellular L-arginine usage for NO
production by some cell types and tissues (171, 294). They also indicate that transport
into the cell was fast (within seconds), relative to the rate of intracellular L-arginine
metabolism (minutes). MCAT-2B, a member of the cationic amino acid transporter
family, is upregulated by LPS stimulation of macrophages (52, 53), making this
transporter a possible candidate for mediating the L-arginine influx. The forced
convection cell culture system could be a useful tool to investigate possible MCAT-2B
involvement, and the potential requirement for extracellular L-arginine.
One limitation of this experiment is that the L-arginine deficient media contained
0.1% FBS. Plasma concentrations of L-arginine are typically 50 to 200 µM (286), and
could explain the residual NO production observed; residual NO production was ~ 75
nM, and L-arginine concentration due to the addition of 0.1% FBS is estimated to be as
high as 200 nM. However, intracellular conversion of L-citrulline to L-arginine via
argininosuccinate synthase and argininosuccinate lyase is also possible (186, 187). These
experiments need to be repeated in media without L-arginine or FBS to evaluate the
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contribution of intracellular L-arginine supply to NO production by LPS and IFNγ
stimulated RAW 264.7 cells.
The effect of hypoxia on the kinetics of L-arginine transport and metabolism was
not investigated. Hypoxia has also been shown to upregulate MCAT-2B mRNA (169),
which would theortically increase L-arginine influx. In contrast, both hypoxia (24 hours)
alone and in combination with LPS has been shown to upregulate macrophage arginase
(7, 169), which has been proposed to compete with iNOS for L-arginine as a substrate
(48, 108, 250). Inhibition of arginase can increase NO production by stimulated
macrophages, and vice versa (109). However, IFNγ stimulation of RAW 264.7 cells did
not induce arginase (270), and costimulation of RAW 264.7 cells with LPS and IFNγ
prevented arginase upregulation by an unknown mechanism (270). Thus, minimal
arginase should have been present in RAW 264.7 cells following overnight stimulation
with LPS and IFNγ as described for this experiment and in Chapters 1 and 2.
The duration of hypoxia required to upregulate arginase, and the effect of
combined stimulation with LPS, IFNγ, and hypoxia on arginase expression and activity,
have not been investigated. Because maximal arginase mRNA and protein upregulation
by LPS (240, 270), cAMP (188), and dexamethasone (188) requires approximately 12
hours, it is unlikely that the hypoxic exposures used in our experiments (Chapter 1: 40
minutes; Chapter 2: 4 hours) were long enough to elicit an increase in arginase.
Furthermore, L-arginine is required for iNOS dimerization, which was either increased
(Chapter 1) or maintained (Chapter 2) with hypoxia in our experiments. Therefore, Larginine availability for iNOS does not appear to be compromised by arginase in the
experiments described in Chapters 1 and 2.
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In summary, these data suggest that NO production predominantly depended on
the continuous transport of extracellular L-arginine into the cell, and that the rate of
transport was faster than the rate of utilization under these conditions. Although the
effects of hypoxia on L-arginine transport and metabolism were not investigated, the
maintenance of iNOS dimerization in Chapters 1 and 2 implied that L-arginine
availability for iNOS was not affected by acute hypoxia. Further study of the
mechanisms and kinetics of L-arginine transport and metabolism by macrophages in the
forced convection cell culture system could help elucidate the physiology of L-arginine
supply for NO production.
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Figure 1.

Effect of Changing Extracellular L-Arginine Concentration on Macrophage NO
production. Representative tracing of NO production by LPS and IFNγ stimulated RAW
264.7 cells exposed to L-arginine deficient media (* 240 seconds), and then returned to
L-arginine replete media (* 3980 seconds) using the forced convection cell culture
system. NO production was continuously measured via an NO electrode; arrows on the x
axis indicate probe baseline checkpoints. Data were baseline corrected. N = 2.
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DISCUSSION

Acute Hypoxic Regulation of NO Production
The ability of macrophages to migrate to sites of infection, injury, and disease
results in their exposure to multiple pO2 [Physiological: 5 to 71 Torr (23, 32, 37, 42, 87,
88, 124, 129, 159, 253, 254, 263, 266, 281, 282); Pathophysiological: 0 to 20 Torr (37,
38, 69, 70, 72, 79, 111, 116, 118, 122, 130, 166, 194, 213, 236, 237)]. Thus,
macrophages are required to operate over a much wider range of pO2 than most cell
types. The studies presented herein are the first to demonstrate the rapidity (seconds) at
which NO production is affected by changes in pO2, the reversible nature of those
changes, and confirm that these changes are occurring within the physiological and
pathophysiological range. This rapid and reversible decrease in NO production following
exposure to acute hypoxia (≤ 4 hours) is due to O2 substrate limitation, and not effects on
iNOS concentration, iNOS dimerization, NADPH availability, or L-arginine availability.
No previous cell culture studies have investigated NO production during acute
hypoxia for direct comparison to these results. The measured apparent KmO2 values
(Chapter 1: 22 ± 6 Torr (218), Chapter 2: 5 ± 1 Torr), however, are within the range of
values reported previously for long term hypoxic exposures ( ≥ 18 hours) of LPS and
IFNγ stimulated macrophages (14 Torr (202), 77 ± 1.4 Torr (179)), and for the isolated
iNOS enzyme (5 ± 0.6 Torr (214), 93 Torr (1), 96 Torr (67)). They are also well within
the range of pO2 required for the regulation of NO production in vivo (0 to 71 Torr (23,
32, 37, 38, 42, 69, 70, 72, 79, 87, 88, 111, 116, 118, 122, 124, 129, 130, 159, 166, 194,
213, 236, 237, 253, 254, 263, 266, 281, 282). The rapidity and reversibility of the
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response within the physiological and pathophysiological pO2 range suggests that
changes in tissue pO2 in vivo will significantly affect macrophage NO production, as has
been suggested previously (1, 67, 179, 202, 214).
Two prior studies investigated the effects of long term hypoxic exposures on
nitrite production by RAW 264.7 cells concurrently stimulated with LPS and IFNγ (179,
202). McCormick et al. measured an apparent KmO2 for the headspace gas of 10.8 ± 2.0
% (77 ± 1.4 Torr) (179). Otto and Baumgardner measured a similar pO2 dependence in a
comparable system, but did not calculate an apparent KmO2 from the nitrite data directly
(202). Instead, they measured iNOS protein concentration and activity, and found that
iNOS protein concentration and activity also decreased as pO2 decreased. Thus, the
changes in nitrite were reflective of changes in the specific activity and/or the amount of
active iNOS, as well as effects due to substrate limitation. After normalizing nitrite
production to changes in iNOS activity, and accounting for the O2 diffusion gradient from
the headspace gas to the cell surface, the estimated apparent KmO2 at the cell surface was
14 Torr (202), similar to the apparent KmO2 values measured in these studies of acute
hypoxia (Chapter 1: 22 ± 6 Torr (218), Chapter 2: 5 ± 1 Torr).
Acute hypoxia did not affect iNOS protein concentration, and iNOS dimerization
was either increased (Chapter 1) or maintained (Chapter 2). These results are consistent
with a previous study showing that costimulation with LPS and hypoxia requires a
minimum of 3 hours and 6 hours to affect iNOS mRNA and protein, respectively (4).
Therefore, the key difference between the regulation of NO production by acute hypoxia
and long term hypoxia appears to be the absence of sufficient time for acute hypoxia to
influence iNOS mRNA and protein concentration. The mechanism for increased iNOS
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dimerization observed in cells cultured with forced convection is not known. Regardless,
decreased NO production despite increased iNOS dimerization further suggests that
substrate limitation is the primary mechanism mediating decreased NO production during
acute hypoxia.
O2 substrate limitation, not decreased NADPH or L-arginine availability, is the
primary mechanism mediating decreased NO production during acute hypoxia.
Macrophage OPPC activity linearly correlated with NO production at all pO2, consistent
with previous studies in atmospheric O2 (58, 153, 191, 192). OPPC activity was
decreased during acute hypoxia due to the absence of NO production; treatment with
1400W, a specific iNOS inhibitor, significantly reduced OPPC activity in LPS and IFNγ
stimulated macrophages at all pO2. Chemically mediated oxidative stress (HEDS or
PIMO) significantly increased OPPC activity under all conditions tested including
hypoxia, and did not affect NO production (HEDS). These results are consistent with our
measurements in tumor cells (259), and conform with the classical view of decreased
metabolic flux through the OPPC under hypoxia (99, 127, 227), whereby removal of O2
leads to a reducing environment. They additionally demonstrate that the absence of
molecular O2 is not limiting for OPPC activity.
The affect of hypoxia on L-arginine transport and metabolism was not measured
directly. However, L-arginine is required for iNOS dimerization (20). Thus, the increase
(Chapter 1) or maintenance (Chapter 2) of iNOS dimerization measured in these studies
suggests L-arginine was not limiting. These results were expected, because the
concentration of L-arginine in the media used for these studies (JBMEM: 300 µM, MEM:
700 µM) was much greater than the L-arginine apparent Km (3 µM) (245). Interestingly,
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the removal of L-arginine also rapidly and reversibly decreased NO production to 20% of
basal levels (Chapter 3). NO production decreased more slowly upon the removal of Larginine (minutes) than upon the removal of O2 (seconds), also suggesting the hypoxia
mediated decrease in NO production was not due to limited L-arginine influx. In
contrast, restoration of L-arginine immediately (seconds) enabled NO production to
resume at levels equivalent to the initial measured level. The forced convection cell
culture system promises to be a useful tool for studying the effect of changes in
extracellular L-arginine transport on NO production.
In summary, changes in physiological and pathophysiological pO2 rapidly and
reversibly regulate macrophage NO production via O2 substrate limitation. Acute
hypoxia did not alter iNOS protein concentration, increased or maintained iNOS
dimerization, and did not limit NADPH availability. Because long term hypoxic
exposure mediates changes in NO production via effects on iNOS protein in addition to
substrate limitation, identifying the degree and duration of hypoxia in vivo will be critical
to assessing its influence on physiological and pathophysiological macrophage NO
production.

Implications for Macrophage NO Physiology and Pathology
Several macrophage phenotypes produce NO (14, 102, 210, 233, 234), and NO
production is essential for eliminating certain types of bacterial and parasitic infections
(6, 94, 96, 215, 265). However, tissue pO2 varies widely, and tissues become hypoxic in
the wound environment, and during many inflammatory diseases such as sepsis and
cancer (116, 194, 213, 236). The studies presented herein suggest that NO production by
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macrophages will be rapidly limited by low pO2 in vivo. Additionally, changes in
extracellular L-arginine could rapidly affect macrophage NO production in vivo.
The center of the wound environment is hypoxic and depleted of L-arginine (7,
225). NO production and L-arginine metabolism by wound macrophages are affected by
hypoxia. During hypoxia, wound macrophages metabolize L-arginine by arginase
instead of iNOS (7). This switch is thought to mediate the transition from the
inflammatory phase of wound healing to the proliferative phase (99). However, once
angiogenesis and revascularization restore O2 to the wound, redirection of L-arginine
back to iNOS may result in overlap of the inflammatory phase and the proliferative
phase, as has been proposed previously (105). Spatial and temporal measurements of
tissue pO2, NO production, and angiogenesis during wound healing would provide further
insight into the sequence, duration, and overlap of these events.
Sepsis is by definition a systemic inflammatory response to infection (36), and
can be thought of as a systemic wound. iNOS expressing macrophages in the heart, lung,
liver, and kidney have been observed via immunohistochemistry during the first 24 hours
in a rat endotoxemia model (44), which is similar to when of iNOS expressing
macrophages appear in a localized wound (24 to 72 hours) (211). Also similar to the
wound environment, septic patients become hypoxic (118), and L-arginine plasma
concentrations decrease (78), albeit by different mechanisms. The results described
herein suggest that macrophage NO production may be limited in septic patients due to
decreased O2 and L-arginine availability, as previously proposed (1, 7, 41, 62, 67, 94,
168, 179, 202, 214, 219). Spatial and temporal measurements of pO2, NO production,
and L-arginine concentration and turnover in septic models and/or patients are necessary
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to verify these results in vivo. If these findings are confirmed, diminished macrophage
function as a result of hypoxia and L-arginine depletion could promote overwhelming
infection, making it questionable as to whether specific iNOS inhibitors will provide
therapeutic value for patients in septic shock. Preventing circulatory collapse, while
enabling macrophages to fight off the infection, may be a more appropriate therapeutic
strategy for patients in the later stages of sepsis.
Chronic inflammation and hypoxia correlate with tumor development and
progression (37, 38, 69, 70, 79, 111, 162, 166). The results herein suggest that
macrophage, and possibly tumor, NO production will be rapidly and reversibly limited
within hypoxic areas. Similar to wound macrophages, TAM in a hypoxic environment
may preferentially metabolize L-arginine via arginase (7). Arginase production of
ornithine promotes cell growth, and may enable tumor growth (184). Furthermore, the
results herein suggest that NO production could be restored once angiogenesis improves
O2 delivery to the tumor. Thus, spatial and temporal measurements of pO2, NO
production, and ornithine production, and identification of the cell types involved, are
needed to verify these results in vivo, and could further our understanding of how these
factors contribute to tumor progression and metastasis.

Conclusions
The pO2 dependence of NO production occurs within the physiological and
pathophysiological range. Acute hypoxia rapidly and reversibly decreases macrophage
NO production. O2 substrate limitation is responsible for decreased NO production
during acute hypoxic exposures; no effects were attributable to changes in iNOS protein
92

concentration, iNOS dimerization, NADPH availability, or albeit indirectly, L-arginine
availability. The primary differences observed between long term hypoxia and acute
hypoxia appear to be the additional affects of long term hypoxia on iNOS mRNA and
protein concentration. Modification of extracellular L-arginine concentration also rapidly
and reversibly regulates macrophage NO production. Acute hypoxia did not appear to
limit L-arginine availability. However, the effects of short and long term hypoxia on Larginine transport and metabolism requires further investigation. Both tissue pO2 and Larginine concentration may significantly influence macrophage NO production and
function in vivo. Further studies of the tissue microenvironment, and its effects on
macrophage NO production, are required to understand its contribution to the
pathogenesis of disease.
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APPENDIX: HYPOXIC CELL CULTURE

Challenges of Hypoxic Cell Culture
Hypoxic cell culture is typically performed using an airtight chamber in which the
gas phase overlying the media, or headspace gas, is tightly controlled. There are several
limitations to this system that limit accurate and precise delivery of O2 to the cells. When
the media is not stirred, the poor solubility of O2 in media forces investigators to use a
long equilibration time to acquire hypoxic conditions (22). Diffusion of oxygen through
the media is so slow, that the predicted pO2 calculated based on diffusion alone (i.e. in the
absence of convection currents) is 0 Torr at 1 mm below the media surface for a
headspace gas of 40 Torr (22). Thus, convection currents, due to temperature gradients
and vibrational changes in the environment, are responsible for the majority of the O2
delivery to the cell monolayer. Since these currents depend on the environment, the
resulting pO2 at the cell monolayer is highly variable within and between cultures, as was
confirmed in our laboratory (202). Another common problem experimenters face is that
many of the materials commonly used for conventional cell culture absorb O2 from room
air and release substantial amounts into the media during “controlled” anoxia (242).
These limitations were overcome using the two cell culture systems described below.

Forced Convection Cell Culture
The forced convection cell culture system (Chapter 1, Figure 1) uses
countercurrent exchange to equilibrate the media with a gas mixture before pumping the
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media through a capillary tube containing the adherent cells (22). None of the materials
used in this system absorb or release O2. Thus, accurate and precise amounts of O2 can
be delivered to the cells, and immediate changes between pO2 can be performed. The
outflow from this system immediately flows past two ports where various probes can be
inserted. In these studies, a NO probe was used to record real-time NO production by the
cells. The response time and sensitivity of the probe is such that physiologic changes in
NO can be detected with as few as 1 X 106 cells in less than 5 seconds from its
production. One disadvantage of this system is the limited number of cells (1 X 106), and
thus limited sample material (protein and RNA) available for analysis.

Thin Film Cell Culture
The thin film cell culture system uses reduced media volume and constant mixing
to accurately deliver O2 to a cell monolayer (143). The headspace pO2 is controlled by
placing the glass dishes or vials into leak proof aluminum chambers, and subjecting them
to a series of gas exchanges with N2 or O2 to produce the desired headspace pO2 (142144, 259). Chambers are warmed to 37°C and shaken continuously to ensure adequate
gas exchange between the headspace and the media throughout the experiment. The pO2
in the chambers is measured at the end of the incubation period using a polarographic O2
electrode. Additionally, EF5, a nitroimidazole, can be used to verify that the cellular pO2
is equivalent to the headspace pO2 (141, 142). One disadvantage of this system is the
slower equilibration time between the headspace pO2 and the O2 tension at the cell
monolayer (~ 30 minutes).
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